pyrazinamide has been researched along with Tuberculosis, Drug-Resistant in 294 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyrazinamide (PZA) is one of the first-line anti-tuberculous drugs used in the treatment of tuberculosis (TB)." | 8.12 | [Investigation of pncA, rpsA and panD Gene Mutations Associated with Resistance in Pyrazinamide-Resistant Mycobacterium tuberculosis Isolates and Spoligotyping]. ( Aslan, G; Aslantürk, A; Biçmen, C; Kayar, MB; Özgür, D; Tezcan Ülger, S; Ülger, M, 2022) |
| "TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China." | 8.12 | Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022) |
| "Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children." | 7.88 | Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018) |
| "Pyrazinamide (PZA) plays a unique role in the treatment for multidrug-resistant tuberculosis (MDR-TB) in both first- and second-line regimens." | 7.85 | Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. ( Hu, Y; Liu, J; Pang, Y; Shen, J; Zhao, Y; Zheng, H; Zhu, D, 2017) |
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 7.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| "Pyrazinamide (PZA) is a first line agent for the treatment of active tuberculosis." | 7.80 | Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California. ( Budzik, JM; Grinsdale, J; Higashi, J; Hopewell, PC; Jarlsberg, LG; Kato-Maeda, M; Nahid, P, 2014) |
| "Pyrazinamide (PZA) is an important first-line tuberculosis drug that is part of the currently used short-course tuberculosis chemotherapy." | 7.70 | pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. ( Cheng, SJ; Heifets, L; Sanchez, T; Thibert, L; Zhang, Y, 2000) |
| "We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents." | 7.69 | Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994) |
| "Pyrazinamide resistance was found in 6/80 (7." | 5.72 | Pyrazinamide resistance in rifampicin discordant tuberculosis. ( Mlisana, KP; Mvelase, NR; Singh, R; Swe Swe-Han, K, 2022) |
| "Pyrazinamide (PZA) is an essential first-line tuberculosis drug for its unique mechanism of action active against multidrug-resistant-TB (MDR-TB)." | 5.41 | Global status of phenotypic pyrazinamide resistance in ( Ghanavati, R; Heidari, H; Kazemian, H; Koohsar, F; Kouhsari, E; Molaeipour, L; Tang, Z; Wang, Z, 2023) |
| "Pyrazinamide (PZA) is one of the first-line anti-tuberculous drugs used in the treatment of tuberculosis (TB)." | 4.12 | [Investigation of pncA, rpsA and panD Gene Mutations Associated with Resistance in Pyrazinamide-Resistant Mycobacterium tuberculosis Isolates and Spoligotyping]. ( Aslan, G; Aslantürk, A; Biçmen, C; Kayar, MB; Özgür, D; Tezcan Ülger, S; Ülger, M, 2022) |
| "TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China." | 4.12 | Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022) |
| "Regimens that could treat both rifampin-resistant (RR) and rifampin-susceptible tuberculosis (TB) while shortening the treatment duration have reached late-stage clinical trials." | 3.91 | Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations. ( Cook-Scalise, S; Denkinger, CM; Dowdy, DW; Kendall, EA; Malhotra, S, 2019) |
| "We report the case of a 10-year-old child treated for latent tuberculosis infection (LTBI) with pyrazinamide (PZA) and levofloxacin after contact with a smear-positive multidrug-resistant tuberculosis adult." | 3.91 | Drug-Induced Fulminant Hepatitis in a Child Treated for Latent Multidrug-Resistant Tuberculosis With Dual Therapy Combining Pyrazinamide and Levofloxacin. ( Ader, F; Collardeau-Frachon, S; Gillet, Y; Huguet, A; Ohlmann, C, 2019) |
| "Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children." | 3.88 | Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018) |
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 3.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| "Pyrazinamide (PZA) plays a unique role in the treatment for multidrug-resistant tuberculosis (MDR-TB) in both first- and second-line regimens." | 3.85 | Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. ( Hu, Y; Liu, J; Pang, Y; Shen, J; Zhao, Y; Zheng, H; Zhu, D, 2017) |
| "Pyrazinamide (PZA) is a first line agent for the treatment of active tuberculosis." | 3.80 | Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California. ( Budzik, JM; Grinsdale, J; Higashi, J; Hopewell, PC; Jarlsberg, LG; Kato-Maeda, M; Nahid, P, 2014) |
| "Pyrazinamide (PZA) is an important first-line tuberculosis drug that is part of the currently used short-course tuberculosis chemotherapy." | 3.70 | pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. ( Cheng, SJ; Heifets, L; Sanchez, T; Thibert, L; Zhang, Y, 2000) |
| "We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents." | 3.69 | Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994) |
| "The duration of the standard treatment for tuberculosis can be shortened to four months but this treatment regimen is also based on rifapentine, in addition to isoniazid, pyrazinamide, and moxifloxacin." | 3.01 | [Treatment of tuberculosis: what is new?] ( Brehm, TT; Friesen, I; Heyckendorf, J; Kalsdorf, B; Kandulla, J; Köhler, N; Kuhns, M; Lange, C; Martensen, J; Schmiedel, S; Terhalle, E, 2023) |
| "Pyrazinamide is a first-line tuberculosis therapy that shortens prophylactic duration from twelve to six months." | 3.01 | Anti-Tubercular Activity of Pyrazinamide Conjugates: Synthesis and Structure-Activity Relationship Studies. ( Chawla, PA; Sharma, S; Wahan, SK, 2023) |
| "Linezolid improves the treatment outcomes of multidrug-resistant tuberculosis substantially." | 2.90 | Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. ( Ahn, H; Cho, YJ; Choi, HS; Choi, SM; Hahn, S; Han, J; Heo, EY; Hwang, YR; Jeong, I; Jo, YS; Joh, JS; Ki, J; Kim, DK; Kim, H; Kim, HS; Kim, J; Kim, SJ; Kwak, N; Lee, CH; Lee, J; Lee, JH; Lee, JK; Lee, JY; Lee, M; Lee, SH; Lee, SM; Lee, YJ; Lim, JN; Park, JH; Park, JS; Park, SS; Park, YS; Song, T; Yim, JJ; Yoon, HI, 2019) |
| "Outcomes of treatment of tuberculosis patients with regimens including pretomanid have not yet been systematically reviewed." | 2.82 | Pretomanid for tuberculosis: a systematic review. ( de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A, 2022) |
| " We also assessed safety and tolerability by monitoring adverse events." | 2.80 | Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul ( Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F, 2015) |
| "Fifty patients with drug-resistant pulmonary tuberculosis were managed by withdrawing all anti-tuberculosis drugs until the results of a drug sensitivity test were obtained (approximately 3 months), and then a 12-month self-administered regimen with four to six anti-tuberculosis drugs at full daily doses was initiated, based primarily on the sensitivity test and secondarily on the history of previous treatment." | 2.70 | Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. ( Martínez-Rossier, LA; Pérez-Guzmán, C; Torres-Cruz, A; Vargas, MH; Villarreal-Velarde, H, 2002) |
| "Pyrazinamide (PZA) is a cornerstone antimicrobial drug used exclusively for the treatment of tuberculosis (TB)." | 2.66 | The Bewildering Antitubercular Action of Pyrazinamide. ( Baughn, AD; Dillon, NA; Lamont, EA, 2020) |
| "Traditionally children have been treated for tuberculosis (TB) based on data extrapolated from adults." | 2.66 | Tuberculosis treatment in children: The changing landscape. ( Huynh, J; Marais, BJ; Schaaf, HS; Thwaites, G, 2020) |
| "To supplement previous state-of-art reviews on anti-tuberculosis treatment and to pave the way forward with reference to the current status, we systematically reviewed published literature on clinical research on tuberculosis (TB) over the past decade in the treatment of drug-susceptible and multidrug-resistant TB (MDR-TB), with a focus on drugs, dosing factors and regimens." | 2.52 | Clinical research in the treatment of tuberculosis: current status and future prospects. ( Chang, KC; Sotgiu, G; Yew, WW, 2015) |
| "Treatment of tuberculosis has three major goals: healing the patient, preventing selection of resistant strains and control transmission of tuberculosis." | 2.40 | [Antitubercular chemotherapy]. ( Dautzenberg, B; Jouveshomme, S, 1997) |
| "Pyrazinamide resistance was found in 6/80 (7." | 1.72 | Pyrazinamide resistance in rifampicin discordant tuberculosis. ( Mlisana, KP; Mvelase, NR; Singh, R; Swe Swe-Han, K, 2022) |
| "Pyrazinamide is an important component of both drug-susceptible and drug-resistant tuberculosis treatment regimens." | 1.72 | Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis. ( Allender, C; Engelthaler, DM; Folkerts, M; Heupink, TH; Limberis, J; Metcalfe, JZ; Van Rie, A; Warren, RM; Whitfield, MG, 2022) |
| "Pyrazinamide (PZA) is an important first-line drug used for treatment of both drug-susceptible and PZA-susceptible multidrug-resistant TB." | 1.62 | Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis. ( Davies Forsman, L; Glader, M; Hoffner, S; Mansjö, M; Werngren, J, 2021) |
| "Pyrazinamide resistance was prevalent in 40." | 1.56 | Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China. ( Cobelens, F; van den Hof, S; Wang, S; Xia, H; Zhao, B; Zhao, Y; Zhou, Y, 2020) |
| "This features mimic Gitelman's syndrome which is an autosomal recessive disorder affecting kidneys causing electrolyte disturbances." | 1.56 | Gitelman-like syndrome: A rare complication of using aminoglycosides in tuberculosis - A case report. ( E R, V; Keny, S; Lawande, D; Parrikar, A, 2020) |
| "Pyrazinamide (PZA) is an important anti-tuberculosis drug, which is active against semi-dormant bacilli and used as a component of first-line drugs and drug-resistant tuberculosis regimens." | 1.56 | Pyrazinamide resistance and pncA mutations in drug resistant Mycobacterium tuberculosis clinical isolates from Myanmar. ( Aung, WW; Aye, KT; Ei, PW; Htwe, MM; Lee, JS; Mon, AS; Myint, Z; Nyunt, WW; San, LL; Win, SM; Zaw, NN, 2020) |
| "Tuberculosis is a bacterial infectious disease that is usually transmitted by inhalation of droplets containing the bacteria." | 1.51 | [Tuberculosis]. ( Heyckendorf, J; Kalsdorf, B; Lange, C; Maurer, FP, 2019) |
| " Stochastic PK/pharmacodynamic (PD) simulations were carried out to evaluate current regimen combinations and dosing guidelines in distinct patient strata." | 1.51 | Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. ( Bang, H; Barry, CE; Dartois, V; Eum, S; Fox, WS; Gupta, SV; Lee, M; Savic, RM; Shim, T; Strydom, N; Via, LE; Zimmerman, M, 2019) |
| " Nonlinear mixed-effects modelling using Monolix 2018R1 software was employed to estimate population pharmacokinetic parameters." | 1.51 | Population Pharmacokinetic Modelling of Pyrazinamide and Pyrazinoic Acid in Patients with Multi-Drug Resistant Tuberculosis. ( Mugabo, P; Mulubwa, M, 2019) |
| "Pyrazinamide (PZA) is a key antibiotic for the treatment of drug susceptible tuberculosis." | 1.51 | Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis. ( Andres, S; Beckert, P; Dachsel, B; Feuerriegel, S; Havlicek, J; Labugger, I; Merker, M; Niemann, S; Slickers, P, 2019) |
| "Pyrazinamide (PZA) is a crucial first-line tuberculosis (TB) drug recommended for both drug-susceptible and multidrug-resistant Mycobacterium tuberculosis." | 1.48 | Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China. ( Chen, J; Jin, J; Liu, W; Shen, Y; Sun, F; Wu, J; Wu, Y; Xie, L; Zhang, W; Zhang, Y, 2018) |
| "Pyrazinamide (PZA) is a critical component of current first-line TB therapy." | 1.48 | Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis. ( Braunstein, M; Durham, PG; Hayden, JD; Hickey, AJ; Lin, FC; Miller, BK; Montgomery, SA; Rank, L; Welch, JT; Young, EF; Zulauf, KE, 2018) |
| "Treatment of isoniazid, rifampicin, pyrazinamide with the diagnosis of epituberculosis was started by taking a sample of gastric aspirate culture sample." | 1.48 | [Management and treatment difficulties of multi-drug resistant pulmonary tuberculosis in a pediatric case]. ( Acar, EM; Bayramoğlu, Z; Çalışkan, E; Erköse, G; Hançerli Törün, S; Kılıçaslan, Z; Şatana, D; Somer, A, 2018) |
| "Pyrazinamide (PZA) is an important component of first-line tuberculosis (TB) treatment because of its distinctive capability to kill subpopulations of persister Mycobacterium tuberculosis (MTB)." | 1.48 | Prevalence of Pyrazinamide Resistance in Khyber Pakhtunkhwa, Pakistan. ( Afzal, MT; Ali, S; Khan, MT; Malik, SI; Masood, N; Nadeem, T; Sheed Khan, A; Zeb, MT, 2018) |
| "Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug, resistance to which occurs primarily due to mutations in pncA (Rv2043c) that encodes the pyrazinamidase enzyme responsible for conversion of pro-drug PZA into its active form." | 1.48 | Analysis of mutations in pncA reveals non-overlapping patterns among various lineages of Mycobacterium tuberculosis. ( Ahmed, N; Baddam, R; Kumar, N; Lankapalli, AK; Peacock, SJ; Semmler, T; Wieler, LH, 2018) |
| " Pyrazinamide pharmacokinetic (PK) data from 61 HIV/TB-coinfected patients in South Africa were used in the analysis." | 1.46 | Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. ( Chirehwa, MT; Denti, P; McIlleron, H; Mthiyane, T; Onyebujoh, P; Rustomjee, R; Smith, P, 2017) |
| "Pyrazinamide (PZA) is a frontline antituberculosis (anti-TB) drug used in both first- and second-line treatment regimens." | 1.46 | Pyrazinamide Susceptibility and ( Ahmed, S; Banu, S; Ferdous, SS; Gratz, J; Houpt, E; Pholwat, S; Rahman, A; Rahman, SMM; Uddin, MKM, 2017) |
| " As irrational use and inadequate dosing of anti-TB drugs may contribute to the epidemic of drug-resistant TB, we assessed the drug types and dosages prescribed in the treatment of TB cases in a representative sample of health care facilities in Yunnan." | 1.46 | Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit. ( Chen, J; Chiang, CY; Innes, AL; Li, L; Xu, L, 2017) |
| "Pyrazinamide resistance was assessed in 4972 patients." | 1.43 | Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. ( Alikhanova, N; Andres, S; Cabibbe, AM; Cirillo, DM; Dadu, A; Dean, AS; Dreyer, A; Driesen, M; Floyd, K; Gilpin, C; Hasan, R; Hasan, Z; Hoffner, S; Husain, A; Hussain, A; Ismail, N; Kamal, M; Kimerling, M; Mansjö, M; Mukadi, YD; Mvusi, L; Niemann, S; Omar, SV; Qadeer, E; Raviglione, MC; Rigouts, L; Ruesch-Gerdes, S; Schito, M; Seyfaddinova, M; Skrahina, A; Tahseen, S; Wells, WA; Weyer, K; Zignol, M, 2016) |
| "MDR-TB can be cured successfully with appropriate combination of drugs if adverse events associated with them can be managed aggressively and timely." | 1.43 | Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis. ( Hosmane, GB; Jain, A; Kushwaha, RA; Prasad, R; Singh, A; Srivastava, R, 2016) |
| "Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug, however, there are relatively few available data on PZA resistant (PZA-R) rate in China." | 1.43 | Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China. ( Gao, Q; Gicquel, B; Luo, T; Nsofor, CA; Shen, X; Wu, J; Xu, P; Yang, C; Zhang, Y; Zhu, G, 2016) |
| "A population-based multicenter study of pulmonary tuberculosis (TB) cases was carried out from 2011 to 2013 in four Chinese districts/counties with different geographic and socioeconomic features." | 1.43 | Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China. ( Drobniewski, F; Hoffner, S; Hu, Y; Li, D; Mansjö, M; Werngren, J; Xu, B; Zheng, X, 2016) |
| "The most important adverse drug event was hearing impairment, which occurred in 46 of 106 (43%) patients." | 1.42 | High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. ( Abena Foe, JL; Aït-Khaled, N; Kuaban, C; Noeske, J; Rieder, HL; Trébucq, A, 2015) |
| "Pyrazinamide (PZA) has important sterilizing activity in tuberculosis (TB) chemotherapy." | 1.42 | Epidemiologic Correlates of Pyrazinamide-Resistant Mycobacterium tuberculosis in New York City. ( Ahuja, S; Fallows, D; Kreiswirth, B; Mathema, B; Schluger, N; Verdugo, D, 2015) |
| "Gastrointestinal events, hepatitis, hearing impairment, arthralgia, psychosis, hypothyroidism, visual disturbances, giddiness, peripheral neuropathy, skin reactions, swelling or pain at injection site, anorexia and sleep disturbances were important amongst these." | 1.40 | Profile of adverse drug reactions in drug resistant tuberculosis from Punjab. ( Bharti, H; Bhushan, B; Chander, R; Gupta, A; Kajal, NC; Ranga, V, 2014) |
| "Pyrazinamide (PZA) plays the important role in shortening the tuberculosis treatment period and in treating MDR-TB." | 1.40 | Pyrazinamide susceptibility testing of Mycobacterium tuberculosis by high resolution melt analysis. ( Foongladda, S; Gratz, J; Houpt, E; Juma, SP; Kibiki, G; Kumburu, H; Pholwat, S; Stroup, S; Trangan, V, 2014) |
| " In this article, a case series is presented to illustrate the value of individualized TB drug dosing in four patients with low TB drug concentrations." | 1.38 | Therapeutic drug monitoring in the treatment of tuberculosis patients. ( Aarnoutse, R; Boeree, M; Ijdema, D; Magis-Escurra, C; van den Boogaard, J, 2012) |
| "Pyrazinamide (PZA) is a potent first-line agent for the treatment of tuberculosis (TB) with activity also against a significant part of drug-resistant Mycobacterium tuberculosis strains." | 1.38 | Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing. ( Ängeby, K; Hoffner, S; Juréen, P; Schön, T; Sturegård, E; Werngren, J, 2012) |
| " We studied the effects of Ag85A DNA vaccine alone or in combination with rifampin (RFP) or pyrazinamide (PZA) for the treatment of MDR-TB in mice." | 1.37 | Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs. ( Bai, X; Li, N; Li, Z; Liang, Y; Wang, L; Wu, X; Yang, Y; Yu, Q; Zhang, J, 2011) |
| "Isolated INH-resistant intracranial tuberculoma is rare in adults." | 1.37 | Isoniazid-resistant intracranial tuberculoma treated with a combination of moxifloxacin and first-line anti-tuberculosis medication. ( Achawal, S; Anderson, G; Lee, WY; Ling, M; Thaker, HK, 2011) |
| " However, clinical trial simulations demonstrated that approximately 1% of tuberculosis patients with perfect adherence would still develop MDR-tuberculosis due to pharmacokinetic variability alone." | 1.37 | Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. ( Gumbo, T; Leff, R; Meek, C; Pasipanodya, JG; Srivastava, S, 2011) |
| " Population pharmacokinetic parameters and their variability encountered in tuberculosis patients were utilized in Monte Carlo simulations to determine the probability that particular daily doses of the drugs would achieve or exceed the EC(90) in the epithelial lining fluid of 10,000 tuberculosis patients." | 1.36 | New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ( Gumbo, T, 2010) |
| "Pyrazinamide (PZA) is an important first-line antituberculous drug, which is applied together with INH, RMP, EMB and SM." | 1.36 | [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland]. ( Augustynowicz-Kopeć, E; Napiórkowska, A; Zwolska, Z, 2010) |
| "Pyrazinamide sensitivity was carried out using the BACTEC 7H12 medium." | 1.36 | Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients. ( Irfan, M; Mehfooz, Z; Rao, NA; Soomro, MM, 2010) |
| "tuberculosis isolates from pulmonary tuberculosis patients." | 1.35 | Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. ( Fourie, PB; Grewal, HM; Mannsåker, T; Mphahlele, M; Muthivhi, T; Stavrum, R; Syre, H; Valvatne, H; Weyer, K, 2008) |
| "Pyrazinamide (PZA) is an important first-line drug used for the short-course treatment of tuberculosis in combination with isoniazid and rifampin." | 1.35 | Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran. ( Doustdar, F; Farnia, P; Khosravi, AD, 2009) |
| "MDR-TB can be successfully treated during pregnancy by using a regimen including effective second-line anti-tuberculosis drugs." | 1.33 | [Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy]. ( Ano, H; Danno, K; Han, Y; Kawahara, K; Matsumoto, T; Nagai, T; Takashima, T; Tamura, Y; Tsuyuguchi, I; Yoshida, H, 2006) |
| " Mean +/- SD of Cmax was 9." | 1.32 | Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. ( Chierakul, N; Chindavijak, B; Chulavatnatol, S; Klomsawat, D, 2003) |
| " Given the severity of some of the adverse events, a better understanding of dosing and clearer guidelines for monitoring therapy are imperative if these drugs are to be prescribed together." | 1.31 | Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. ( Dolovich, LR; Holbrook, A; Loeb, M; Papastavros, T; Whitehead, L, 2002) |
| "The frequency of TB recurrence among MDR-TB patients declared 'cured' after short-course chemotherapy is high." | 1.31 | Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy. ( Danilova, ID; Espinal, M; Grzemska, M; Migliori, GB; Punga, VV; Raviglione, MC, 2002) |
| "Two patients with multidrug-resistant pulmonary tuberculosis were surgically treated after 3 and 7 years of unsuccessful chemotherapy." | 1.30 | [Surgical treatment of patients with multi-resistant pulmonary tuberculosis--case reports]. ( Kuś, J; Michałowska-Mitczuk, D, 1997) |
| "Children with AIDS and TB most frequently present with atypical manifestations of TB." | 1.29 | Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome. ( Birnbaum, J; Chan, SP; Rao, M; Steiner, P, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.02) | 18.7374 |
| 1990's | 35 (11.90) | 18.2507 |
| 2000's | 44 (14.97) | 29.6817 |
| 2010's | 161 (54.76) | 24.3611 |
| 2020's | 51 (17.35) | 2.80 |
| Authors | Studies |
|---|---|
| Juréen, P | 2 |
| Werngren, J | 10 |
| Toro, JC | 1 |
| Hoffner, S | 9 |
| Vavříková, E | 1 |
| Polanc, S | 1 |
| Kočevar, M | 1 |
| Horváti, K | 1 |
| Bosze, S | 1 |
| Stolaříková, J | 1 |
| Vávrová, K | 1 |
| Vinšová, J | 1 |
| Hu, YQ | 1 |
| Zhang, S | 1 |
| Zhao, F | 1 |
| Gao, C | 1 |
| Feng, LS | 1 |
| Lv, ZS | 1 |
| Xu, Z | 1 |
| Wu, X | 4 |
| Liu, D | 1 |
| Huang, F | 2 |
| Zhang, G | 1 |
| He, W | 1 |
| Ou, X | 2 |
| He, P | 1 |
| Zhao, B | 3 |
| Zhu, B | 1 |
| Liu, F | 2 |
| Li, Z | 2 |
| Liu, C | 1 |
| Xia, H | 3 |
| Wang, S | 4 |
| Zhou, Y | 5 |
| Walker, TM | 3 |
| Liu, L | 1 |
| Crook, DW | 2 |
| Zhao, Y | 7 |
| Mahmood, N | 1 |
| Bhatti, S | 1 |
| Abbas, SN | 1 |
| Shahid, S | 1 |
| Nasir, SB | 1 |
| Whitfield, MG | 3 |
| Engelthaler, DM | 1 |
| Allender, C | 1 |
| Folkerts, M | 1 |
| Heupink, TH | 1 |
| Limberis, J | 1 |
| Warren, RM | 3 |
| Van Rie, A | 3 |
| Metcalfe, JZ | 1 |
| Nie, Q | 1 |
| Tao, L | 1 |
| Li, Y | 6 |
| Chen, N | 1 |
| Chen, H | 2 |
| Wang, Y | 4 |
| Tang, Q | 2 |
| Wang, X | 4 |
| Huang, C | 1 |
| Yang, C | 2 |
| Jeong, HE | 1 |
| Choi, J | 1 |
| Oh, IS | 1 |
| Son, H | 1 |
| Jang, SH | 1 |
| Jung, SY | 1 |
| Shin, JY | 1 |
| Özgür, D | 1 |
| Tezcan Ülger, S | 1 |
| Kayar, MB | 1 |
| Biçmen, C | 2 |
| Aslantürk, A | 1 |
| Ülger, M | 1 |
| Aslan, G | 1 |
| Jiang, H | 1 |
| Li, X | 3 |
| Xing, Z | 1 |
| Niu, Q | 1 |
| Xu, J | 1 |
| Heysell, SK | 3 |
| Mpagama, SG | 3 |
| Ogarkov, OB | 1 |
| Conaway, M | 1 |
| Ahmed, S | 2 |
| Zhdanova, S | 1 |
| Pholwat, S | 4 |
| Alshaer, MH | 1 |
| Chongolo, AM | 1 |
| Mujaga, B | 1 |
| Sariko, M | 1 |
| Saba, S | 1 |
| Rahman, SMM | 2 |
| Uddin, MKM | 2 |
| Suzdalnitsky, A | 1 |
| Moiseeva, E | 1 |
| Zorkaltseva, E | 1 |
| Koshcheyev, M | 1 |
| Vitko, S | 1 |
| Mmbaga, BT | 2 |
| Kibiki, GS | 3 |
| Pasipanodya, JG | 4 |
| Peloquin, CA | 4 |
| Banu, S | 2 |
| Houpt, ER | 4 |
| Ding, Y | 1 |
| Zhu, H | 1 |
| Fu, L | 2 |
| Zhang, W | 5 |
| Wang, B | 2 |
| Guo, S | 1 |
| Chen, X | 3 |
| Wang, N | 1 |
| Liu, H | 1 |
| Lu, Y | 1 |
| Mesfin, EA | 2 |
| Merker, M | 2 |
| Beyene, D | 2 |
| Tesfaye, A | 2 |
| Shuaib, YA | 1 |
| Addise, D | 2 |
| Tessema, B | 2 |
| Niemann, S | 4 |
| Min, J | 1 |
| Kim, HW | 1 |
| Kang, JY | 1 |
| Kim, SK | 1 |
| Kim, JW | 1 |
| Kim, YH | 2 |
| Yoon, HK | 1 |
| Lee, SH | 5 |
| Kim, JS | 4 |
| Wahan, SK | 1 |
| Sharma, S | 1 |
| Chawla, PA | 1 |
| Mvelase, NR | 1 |
| Singh, R | 1 |
| Swe Swe-Han, K | 1 |
| Mlisana, KP | 1 |
| Brankin, A | 1 |
| Seifert, M | 1 |
| Georghiou, SB | 1 |
| Uplekar, S | 1 |
| Suresh, A | 1 |
| Colman, RE | 1 |
| Jones, AJ | 1 |
| Mathad, JS | 1 |
| Dooley, KE | 2 |
| Eke, AC | 1 |
| Lyons, MA | 1 |
| Mok, J | 3 |
| Lee, M | 5 |
| Kim, DK | 4 |
| Jhun, BW | 3 |
| Jo, KW | 5 |
| Jeon, D | 4 |
| Lee, T | 4 |
| Lee, JY | 4 |
| Park, JS | 5 |
| Kang, YA | 3 |
| Lee, JK | 4 |
| Kwak, N | 3 |
| Ahn, JH | 3 |
| Shim, TS | 5 |
| Kim, SY | 5 |
| Kim, S | 3 |
| Kim, K | 2 |
| Seok, KH | 2 |
| Yoon, S | 2 |
| Kim, YR | 4 |
| Kim, J | 4 |
| Yim, D | 2 |
| Hahn, S | 4 |
| Cho, SN | 3 |
| Yim, JJ | 4 |
| Paton, NI | 1 |
| Cousins, C | 1 |
| Suresh, C | 1 |
| Burhan, E | 1 |
| Chew, KL | 1 |
| Dalay, VB | 1 |
| Lu, Q | 1 |
| Kusmiati, T | 1 |
| Balanag, VM | 1 |
| Lee, SL | 1 |
| Ruslami, R | 1 |
| Pokharkar, Y | 1 |
| Djaharuddin, I | 1 |
| Sugiri, JJR | 1 |
| Veto, RS | 1 |
| Sekaggya-Wiltshire, C | 1 |
| Avihingsanon, A | 1 |
| Sarin, R | 1 |
| Papineni, P | 1 |
| Nunn, AJ | 3 |
| Crook, AM | 2 |
| Modlin, SJ | 1 |
| Mansjö, M | 7 |
| Ejike, CM | 1 |
| Hoffner, SE | 1 |
| Valafar, F | 1 |
| Lopez, JM | 1 |
| Zimic, M | 1 |
| Vallejos, K | 1 |
| Sevilla, D | 1 |
| Quispe-Carbajal, M | 1 |
| Roncal, E | 1 |
| Rodríguez, J | 2 |
| Antiparra, R | 1 |
| Arteaga, H | 1 |
| Gilman, RH | 1 |
| Maruenda, H | 1 |
| Sheen, P | 1 |
| Zhu, J | 1 |
| Liu, J | 2 |
| Bao, Z | 1 |
| Cao, H | 1 |
| Ning, Z | 1 |
| Hu, Y | 4 |
| Davies Forsman, L | 3 |
| Li, R | 2 |
| Jia, L | 1 |
| Yu, H | 1 |
| Huang, Y | 1 |
| Wu, Q | 1 |
| Xiao, M | 1 |
| Ge, S | 2 |
| Zhang, Y | 12 |
| Feng, Z | 1 |
| Li, Q | 3 |
| Xu, Y | 1 |
| Shi, W | 1 |
| Sun, F | 4 |
| Wang, Z | 2 |
| Tang, Z | 1 |
| Heidari, H | 1 |
| Molaeipour, L | 1 |
| Ghanavati, R | 1 |
| Kazemian, H | 1 |
| Koohsar, F | 1 |
| Kouhsari, E | 1 |
| Brehm, TT | 1 |
| Köhler, N | 1 |
| Schmiedel, S | 1 |
| Terhalle, E | 1 |
| Martensen, J | 1 |
| Kalsdorf, B | 2 |
| Kandulla, J | 1 |
| Heyckendorf, J | 2 |
| Kuhns, M | 1 |
| Friesen, I | 1 |
| Lange, C | 2 |
| Mushtaq, F | 1 |
| Raza, SM | 1 |
| Ahmad, A | 1 |
| Aslam, H | 1 |
| Adeel, A | 1 |
| Saleem, S | 1 |
| Ahmad, I | 2 |
| Kendall, EA | 1 |
| Malhotra, S | 1 |
| Cook-Scalise, S | 1 |
| Denkinger, CM | 2 |
| Dowdy, DW | 2 |
| Rangnekar, B | 1 |
| Momin, MAM | 2 |
| Eedara, BB | 1 |
| Sinha, S | 1 |
| Das, SC | 2 |
| Maurer, FP | 1 |
| Tweed, CD | 1 |
| Dawson, R | 3 |
| Burger, DA | 3 |
| Conradie, A | 2 |
| Mendel, CM | 3 |
| Conradie, F | 1 |
| Diacon, AH | 5 |
| Ntinginya, NE | 2 |
| Everitt, DE | 1 |
| Haraka, F | 1 |
| Li, M | 2 |
| van Niekerk, CH | 1 |
| Okwera, A | 1 |
| Rassool, MS | 1 |
| Reither, K | 2 |
| Sebe, MA | 1 |
| Staples, S | 1 |
| Variava, E | 2 |
| Spigelman, M | 3 |
| van den Hof, S | 2 |
| Cobelens, F | 2 |
| Genestet, C | 1 |
| Hodille, E | 1 |
| Berland, JL | 1 |
| Ginevra, C | 1 |
| Bryant, JE | 1 |
| Ader, F | 2 |
| Lina, G | 1 |
| Dumitrescu, O | 1 |
| Cho, HJ | 1 |
| Lim, YJ | 1 |
| Koh, WJ | 4 |
| Song, CH | 1 |
| Kang, MW | 1 |
| Faraj, A | 1 |
| Svensson, RJ | 1 |
| Simonsson, USH | 1 |
| Park, S | 2 |
| Decroo, T | 3 |
| de Jong, BC | 4 |
| Piubello, A | 2 |
| Souleymane, MB | 2 |
| Lynen, L | 2 |
| Van Deun, A | 6 |
| Miyahara, S | 1 |
| von Groote-Bidlingmaier, F | 3 |
| Sun, X | 1 |
| Hafner, R | 1 |
| Rosenkranz, SL | 1 |
| Ignatius, EH | 1 |
| Nuermberger, EL | 3 |
| Moran, L | 1 |
| Donahue, K | 1 |
| Swindells, S | 1 |
| Vanker, N | 1 |
| Lamont, EA | 1 |
| Dillon, NA | 1 |
| Baughn, AD | 1 |
| Huynh, J | 1 |
| Thwaites, G | 1 |
| Marais, BJ | 1 |
| Schaaf, HS | 6 |
| Naluyange, R | 1 |
| Mboowa, G | 1 |
| Komakech, K | 1 |
| Semugenze, D | 1 |
| Kateete, DP | 1 |
| Ssengooba, W | 2 |
| Ghosh, A | 1 |
| N, S | 1 |
| Saha, S | 1 |
| Desai, U | 1 |
| Doshi, K | 1 |
| Joshi, JM | 1 |
| Köser, CU | 2 |
| Cirillo, DM | 4 |
| Miotto, P | 2 |
| E R, V | 1 |
| Parrikar, A | 1 |
| Keny, S | 1 |
| Lawande, D | 1 |
| Lempens, P | 1 |
| Aung, KJM | 1 |
| Hossain, MA | 2 |
| Rigouts, L | 4 |
| Meehan, CJ | 2 |
| Tahseen, S | 2 |
| Khanzada, FM | 1 |
| Rizvi, AH | 1 |
| Qadir, M | 1 |
| Ghazal, A | 1 |
| Baloch, AQ | 1 |
| Mustafa, T | 1 |
| Wilson, M | 1 |
| O'Connor, B | 1 |
| Matigian, N | 1 |
| Eather, G | 1 |
| Kuhlin, J | 2 |
| Jonsson Nordvall, M | 1 |
| Wijkander, M | 3 |
| Wagrell, C | 2 |
| Jonsson, J | 2 |
| Groenheit, R | 2 |
| Schön, T | 3 |
| Bruchfeld, J | 2 |
| Ei, PW | 2 |
| Mon, AS | 2 |
| Htwe, MM | 2 |
| Win, SM | 2 |
| Aye, KT | 2 |
| San, LL | 1 |
| Zaw, NN | 1 |
| Nyunt, WW | 2 |
| Myint, Z | 1 |
| Lee, JS | 3 |
| Aung, WW | 2 |
| Weng, T | 1 |
| Chen, J | 3 |
| Wahid, A | 1 |
| Ahmad, N | 3 |
| Ghafoor, A | 1 |
| Latif, A | 1 |
| Saleem, F | 1 |
| Khan, S | 1 |
| Atif, M | 1 |
| Iqbal, Q | 1 |
| Fernandez Do Porto, DA | 1 |
| Monteserin, J | 1 |
| Campos, J | 1 |
| Sosa, EJ | 1 |
| Matteo, M | 1 |
| Serral, F | 1 |
| Yokobori, N | 1 |
| Benevento, AF | 1 |
| Poklepovich, T | 1 |
| Pardo, A | 1 |
| Wainmayer, I | 1 |
| Simboli, N | 1 |
| Castello, F | 1 |
| Paul, R | 2 |
| Martí, M | 1 |
| López, B | 1 |
| Turjanski, A | 1 |
| Ritacco, V | 1 |
| Che, Y | 1 |
| Bo, D | 1 |
| Lin, X | 1 |
| Chen, T | 1 |
| He, T | 1 |
| Lin, Y | 1 |
| Glader, M | 1 |
| Gils, T | 1 |
| Sun, W | 1 |
| Wu, Z | 1 |
| Xia, F | 1 |
| Wang, J | 1 |
| Yang, J | 1 |
| Yu, F | 1 |
| Yang, H | 1 |
| Xiao, H | 1 |
| Fan, L | 1 |
| Marks, SM | 1 |
| Mase, SR | 1 |
| Morris, SB | 1 |
| Dalcolmo, M | 1 |
| Gayoso, R | 1 |
| Sotgiu, G | 4 |
| D'Ambrosio, L | 2 |
| Rocha, JL | 1 |
| Borga, L | 1 |
| Fandinho, F | 1 |
| Braga, JU | 1 |
| Galesi, VM | 1 |
| Barreira, D | 1 |
| Sanchez, DA | 1 |
| Dockhorn, F | 1 |
| Centis, R | 2 |
| Caminero, JA | 1 |
| Migliori, GB | 5 |
| Kim, HJ | 4 |
| Yoon, HH | 1 |
| Eun, BW | 1 |
| Ahn, Y | 1 |
| Ryoo, S | 2 |
| Anthony, RM | 2 |
| Cynamon, M | 1 |
| den Hertog, AL | 1 |
| van Soolingen, D | 4 |
| Fofana, MO | 1 |
| Chirehwa, MT | 1 |
| McIlleron, H | 2 |
| Rustomjee, R | 1 |
| Mthiyane, T | 1 |
| Onyebujoh, P | 1 |
| Smith, P | 1 |
| Denti, P | 2 |
| Nusrath Unissa, A | 1 |
| Hanna, LE | 1 |
| Rahman, A | 1 |
| Ferdous, SS | 1 |
| Gratz, J | 4 |
| Houpt, E | 2 |
| Sengstake, S | 1 |
| Bergval, IL | 1 |
| Schuitema, AR | 1 |
| de Beer, JL | 1 |
| Phelan, J | 1 |
| de Zwaan, R | 1 |
| Clark, TG | 1 |
| Calderón, RI | 2 |
| Velásquez, GE | 2 |
| Becerra, MC | 3 |
| Zhang, Z | 3 |
| Contreras, CC | 2 |
| Yataco, RM | 2 |
| Galea, JT | 2 |
| Lecca, LW | 2 |
| Kritski, AL | 1 |
| Murray, MB | 2 |
| Mitnick, CD | 4 |
| Srivastava, S | 2 |
| Gumbo, T | 4 |
| Lee, SD | 1 |
| Kim, WS | 1 |
| Willby, MJ | 1 |
| Havumaki, J | 1 |
| Johnson, K | 1 |
| Posey, JE | 1 |
| Xu, L | 1 |
| Innes, AL | 1 |
| Li, L | 2 |
| Chiang, CY | 2 |
| Pang, Y | 3 |
| Zhu, D | 1 |
| Zheng, H | 2 |
| Shen, J | 1 |
| Putim, C | 1 |
| Phaonakrop, N | 1 |
| Jaresitthikunchai, J | 1 |
| Gamngoen, R | 1 |
| Tragoolpua, K | 1 |
| Intorasoot, S | 1 |
| Anukool, U | 1 |
| Tharincharoen, CS | 1 |
| Phunpae, P | 1 |
| Tayapiwatana, C | 1 |
| Kasinrerk, W | 1 |
| Roytrakul, S | 1 |
| Butr-Indr, B | 1 |
| van der Laan, LE | 1 |
| Garcia-Prats, AJ | 3 |
| Tikiso, T | 1 |
| Wiesner, L | 1 |
| de Kock, M | 1 |
| Winckler, J | 1 |
| Norman, J | 1 |
| Hesseling, AC | 2 |
| Lee, H | 1 |
| Park, HY | 1 |
| Jeon, K | 1 |
| Huh, HJ | 1 |
| Lee, NY | 1 |
| Jeong, BH | 1 |
| Yang, Y | 2 |
| Niehaus, KE | 1 |
| Iqbal, Z | 1 |
| Walker, AS | 1 |
| Wilson, DJ | 1 |
| Peto, TEA | 1 |
| Smith, EG | 1 |
| Zhu, T | 1 |
| Clifton, DA | 1 |
| Aung, ST | 1 |
| Chang, CL | 2 |
| Chang, KC | 4 |
| Yew, WW | 4 |
| Liu, W | 1 |
| Shen, Y | 1 |
| Jin, J | 1 |
| Wu, J | 2 |
| Wu, Y | 1 |
| Xie, L | 1 |
| Al-Mutairi, NM | 2 |
| Ahmad, S | 2 |
| Mokaddas, E | 2 |
| Al Ammari, M | 1 |
| Al Turaiki, A | 1 |
| Al Essa, M | 1 |
| Kashkary, AM | 1 |
| Eltigani, SA | 1 |
| Ahmed, AE | 1 |
| Baddam, R | 1 |
| Kumar, N | 2 |
| Wieler, LH | 1 |
| Lankapalli, AK | 1 |
| Ahmed, N | 1 |
| Peacock, SJ | 2 |
| Semmler, T | 1 |
| Bwalya, P | 1 |
| Yamaguchi, T | 1 |
| Mulundu, G | 1 |
| Nakajima, C | 1 |
| Mbulo, G | 1 |
| Solo, ES | 1 |
| Fukushima, Y | 1 |
| Kasakwa, K | 1 |
| Suzuki, Y | 1 |
| Khan, MT | 1 |
| Malik, SI | 1 |
| Ali, S | 1 |
| Sheed Khan, A | 1 |
| Nadeem, T | 1 |
| Zeb, MT | 1 |
| Masood, N | 1 |
| Afzal, MT | 1 |
| Fregonese, F | 1 |
| Ahuja, SD | 1 |
| Akkerman, OW | 2 |
| Arakaki-Sanchez, D | 1 |
| Ayakaka, I | 1 |
| Baghaei, P | 1 |
| Bang, D | 1 |
| Bastos, M | 1 |
| Benedetti, A | 2 |
| Bonnet, M | 1 |
| Cattamanchi, A | 1 |
| Cegielski, P | 1 |
| Chien, JY | 1 |
| Cox, H | 1 |
| Dedicoat, M | 1 |
| Erkens, C | 1 |
| Escalante, P | 1 |
| Falzon, D | 1 |
| Gegia, M | 1 |
| Gillespie, SH | 1 |
| Glynn, JR | 1 |
| Goldberg, S | 1 |
| Griffith, D | 1 |
| Jacobson, KR | 1 |
| Johnston, JC | 1 |
| Jones-López, EC | 1 |
| Khan, A | 1 |
| Kritski, A | 1 |
| Lan, ZY | 1 |
| Lee, JH | 3 |
| Li, PZ | 1 |
| Maciel, EL | 1 |
| Galliez, RM | 1 |
| Merle, CSC | 1 |
| Munang, M | 1 |
| Narendran, G | 1 |
| Nguyen, VN | 1 |
| Nunn, A | 1 |
| Ohkado, A | 1 |
| Phillips, PPJ | 2 |
| Ponnuraja, C | 1 |
| Reves, R | 1 |
| Romanowski, K | 1 |
| Seung, K | 1 |
| Skrahina, A | 2 |
| Soolingen, DV | 1 |
| Tabarsi, P | 1 |
| Trajman, A | 1 |
| Trieu, L | 1 |
| Banurekha, VV | 1 |
| Viiklepp, P | 1 |
| Wang, JY | 1 |
| Yoshiyama, T | 1 |
| Menzies, D | 2 |
| Hançerli Törün, S | 1 |
| Acar, EM | 1 |
| Somer, A | 1 |
| Erköse, G | 1 |
| Şatana, D | 1 |
| Bayramoğlu, Z | 1 |
| Çalışkan, E | 1 |
| Kılıçaslan, Z | 1 |
| Smith, C | 1 |
| Khaemraev, A | 1 |
| Tigay, Z | 1 |
| Parpieva, N | 1 |
| Tillyashaykhov, M | 1 |
| Achar, J | 1 |
| Hajek, J | 1 |
| Greig, J | 1 |
| du Cros, P | 1 |
| Moore, D | 1 |
| Ismail, NA | 2 |
| Mvusi, L | 2 |
| Nanoo, A | 1 |
| Dreyer, A | 2 |
| Omar, SV | 3 |
| Babatunde, S | 1 |
| Molebatsi, T | 1 |
| van der Walt, M | 1 |
| Adelekan, A | 1 |
| Deyde, V | 1 |
| Ihekweazu, C | 1 |
| Madhi, SA | 1 |
| Karmakar, M | 1 |
| Globan, M | 1 |
| Fyfe, JAM | 1 |
| Stinear, TP | 1 |
| Johnson, PDR | 1 |
| Holmes, NE | 1 |
| Denholm, JT | 1 |
| Ascher, DB | 1 |
| Zuur, MA | 1 |
| van der Werf, TS | 1 |
| Alffenaar, JC | 2 |
| Bouzouita, I | 1 |
| Cabibbe, AM | 2 |
| Trovato, A | 1 |
| Draoui, H | 1 |
| Ghariani, A | 1 |
| Midouni, B | 1 |
| Essalah, L | 1 |
| Mehiri, E | 1 |
| Slim-Saidi, L | 1 |
| Admasu, A | 1 |
| Amare, M | 1 |
| Dagne, B | 1 |
| Yaregal, Z | 1 |
| Tesfaye, E | 1 |
| Pandey, S | 1 |
| Lavu, E | 1 |
| Congdon, J | 1 |
| Moke, R | 1 |
| Bainomugisa, A | 1 |
| Coulter, C | 1 |
| Cao, R | 1 |
| Teskey, G | 1 |
| Islamoglu, H | 1 |
| Abrahem, R | 1 |
| Munjal, S | 1 |
| Gyurjian, K | 1 |
| Zhong, L | 2 |
| Venketaraman, V | 1 |
| Fox, T | 1 |
| Manning, K | 1 |
| Stewart, A | 1 |
| Tiffin, N | 1 |
| Khomo, N | 1 |
| Leslie, J | 1 |
| Boulle, A | 1 |
| Mudaly, V | 1 |
| Kock, Y | 1 |
| Meintjes, G | 1 |
| Wasserman, S | 1 |
| Doan, TN | 1 |
| Cao, P | 1 |
| Emeto, TI | 1 |
| McCaw, JM | 1 |
| McBryde, ES | 1 |
| Montgomery, SA | 1 |
| Young, EF | 2 |
| Durham, PG | 2 |
| Zulauf, KE | 1 |
| Rank, L | 1 |
| Miller, BK | 1 |
| Hayden, JD | 2 |
| Lin, FC | 1 |
| Welch, JT | 2 |
| Hickey, AJ | 2 |
| Braunstein, M | 1 |
| Lu, W | 2 |
| Shao, Y | 2 |
| Song, H | 1 |
| Li, G | 1 |
| Zhu, L | 2 |
| Chen, C | 2 |
| Yoon, HI | 1 |
| Jeong, I | 1 |
| Heo, EY | 1 |
| Park, YS | 1 |
| Jo, YS | 1 |
| Park, SS | 1 |
| Lee, SM | 1 |
| Joh, JS | 1 |
| Lee, CH | 1 |
| Lee, J | 2 |
| Choi, SM | 1 |
| Park, JH | 1 |
| Cho, YJ | 2 |
| Lee, YJ | 1 |
| Kim, SJ | 3 |
| Hwang, YR | 1 |
| Kim, H | 3 |
| Ki, J | 1 |
| Lim, JN | 1 |
| Choi, HS | 1 |
| Song, T | 2 |
| Kim, HS | 1 |
| Han, J | 1 |
| Ahn, H | 2 |
| Cornejo Garcia, JG | 1 |
| Alarcón Guizado, VA | 1 |
| Mendoza Ticona, A | 1 |
| Alarcon, E | 1 |
| Heldal, E | 1 |
| Moore, DAJ | 1 |
| Forsman, LD | 2 |
| Hammar, U | 1 |
| Giske, CG | 1 |
| Chen, Y | 1 |
| Guan, W | 1 |
| Jiang, X | 1 |
| Ren, P | 1 |
| Li, J | 1 |
| Shi, J | 1 |
| He, G | 1 |
| Wu, M | 1 |
| Tang, P | 1 |
| Wang, F | 4 |
| Sheng, Y | 1 |
| Zhou, Z | 1 |
| Huang, H | 2 |
| Hong, L | 1 |
| Liu, Q | 2 |
| Walsh, KF | 1 |
| Souroutzidis, A | 1 |
| Vilbrun, SC | 1 |
| Peeples, M | 1 |
| Joissaint, G | 1 |
| Delva, S | 1 |
| Widmann, P | 1 |
| Royal, G | 1 |
| Pry, J | 1 |
| Bang, H | 2 |
| Pape, JW | 1 |
| Koenig, SP | 1 |
| Eldeen, HS | 1 |
| Joseph, S | 1 |
| Mugabo, P | 1 |
| Mulubwa, M | 1 |
| Morales Pérez, C | 1 |
| Gomez-Pastrana, D | 1 |
| Aragón Fernández, C | 1 |
| Pérez Escolano, E | 1 |
| Kim, CK | 1 |
| Shin, S | 1 |
| Shin, SJ | 1 |
| Won, HJ | 1 |
| Jang, JY | 1 |
| Juma, SP | 2 |
| Maro, A | 1 |
| Liyoyo, A | 1 |
| Havlicek, J | 1 |
| Dachsel, B | 1 |
| Slickers, P | 1 |
| Andres, S | 2 |
| Beckert, P | 1 |
| Feuerriegel, S | 2 |
| Labugger, I | 1 |
| Vasava, MS | 1 |
| Nair, SG | 1 |
| Rathwa, SK | 1 |
| Patel, DB | 1 |
| Patel, HD | 1 |
| Strydom, N | 1 |
| Gupta, SV | 1 |
| Fox, WS | 1 |
| Via, LE | 1 |
| Eum, S | 1 |
| Shim, T | 1 |
| Barry, CE | 1 |
| Zimmerman, M | 1 |
| Dartois, V | 1 |
| Savic, RM | 1 |
| Glasauer, S | 1 |
| Altmann, D | 1 |
| Hauer, B | 1 |
| Brodhun, B | 1 |
| Haas, W | 1 |
| Perumal, N | 1 |
| Huguet, A | 1 |
| Ohlmann, C | 1 |
| Collardeau-Frachon, S | 1 |
| Gillet, Y | 1 |
| Pradipta, IS | 1 |
| Van't Boveneind-Vrubleuskaya, N | 1 |
| Hak, E | 1 |
| Li, H | 1 |
| Salinger, DH | 1 |
| Everitt, D | 3 |
| Del Parigi, A | 1 |
| Mendel, C | 2 |
| Nedelman, JR | 1 |
| Stagg, HR | 1 |
| Bothamley, GH | 1 |
| Davidson, JA | 1 |
| Kunst, H | 1 |
| Lalor, MK | 1 |
| Lipman, MC | 1 |
| Loutet, MG | 1 |
| Lozewicz, S | 1 |
| Mohiyuddin, T | 1 |
| Abbara, A | 1 |
| Alexander, E | 1 |
| Booth, H | 1 |
| Creer, DD | 1 |
| Harris, RJ | 1 |
| Kon, OM | 1 |
| Loebinger, MR | 1 |
| McHugh, TD | 1 |
| Milburn, HJ | 1 |
| Palchaudhuri, P | 1 |
| Schmok, E | 1 |
| Taylor, L | 1 |
| Abubakar, I | 1 |
| Ishiwada, N | 1 |
| Tokunaga, O | 1 |
| Nagasawa, K | 1 |
| Ichimoto, K | 1 |
| Kinoshita, K | 1 |
| Hishiki, H | 1 |
| Kohno, Y | 1 |
| Jnawali, HN | 1 |
| Hwang, SC | 1 |
| Park, YK | 2 |
| Lee, YS | 1 |
| Chung, GT | 1 |
| Choe, KH | 1 |
| Dutta, NK | 1 |
| Alsultan, A | 1 |
| Gniadek, TJ | 1 |
| Belchis, DA | 1 |
| Pinn, ML | 1 |
| Mdluli, KE | 2 |
| Karakousis, PC | 1 |
| Kurbatova, EV | 1 |
| Cavanaugh, JS | 1 |
| Dalton, T | 1 |
| Click, ES | 1 |
| Cegielski, JP | 1 |
| Hong, CY | 3 |
| Liu, XL | 3 |
| Arora, J | 1 |
| Sidiq, Z | 1 |
| Visalakshi, P | 1 |
| Bhalla, M | 1 |
| Behera, D | 1 |
| Myneedu, VP | 1 |
| Watcharasamphankul, W | 1 |
| Foongladda, S | 2 |
| Hung, NV | 1 |
| Ando, H | 1 |
| Thuy, TT | 1 |
| Kuwahara, T | 1 |
| Hang, NT | 1 |
| Sakurada, S | 1 |
| Thuong, PH | 1 |
| Lien, LT | 1 |
| Keicho, N | 1 |
| Stroup, S | 2 |
| Trangan, V | 1 |
| Kumburu, H | 2 |
| Kibiki, G | 1 |
| Ndusilo, N | 1 |
| Daum, LT | 1 |
| Fourie, PB | 2 |
| Bhattacharyya, S | 1 |
| Gradus, S | 1 |
| Maningi, NE | 1 |
| Fischer, GW | 1 |
| Adler-Shohet, FC | 1 |
| Low, J | 1 |
| Carson, M | 1 |
| Girma, H | 1 |
| Singh, J | 1 |
| Francis, JR | 1 |
| Blyth, CC | 1 |
| Colby, S | 1 |
| Fagan, JM | 1 |
| Waring, J | 1 |
| Seddon, JA | 1 |
| Budzik, JM | 1 |
| Jarlsberg, LG | 1 |
| Higashi, J | 1 |
| Grinsdale, J | 1 |
| Hopewell, PC | 1 |
| Kato-Maeda, M | 1 |
| Nahid, P | 1 |
| Pandit, S | 1 |
| Choudhury, S | 1 |
| Das, A | 1 |
| Das, SK | 1 |
| Bhattacharya, S | 1 |
| Aono, A | 1 |
| Chikamatsu, K | 1 |
| Yamada, H | 1 |
| Kato, T | 1 |
| Mitarai, S | 1 |
| Comas, I | 1 |
| Gagneux, S | 1 |
| Simons, SO | 1 |
| van der Laan, T | 1 |
| Mulder, A | 1 |
| van Ingen, J | 1 |
| Dekhuijzen, PN | 1 |
| Boeree, MJ | 1 |
| Kedarisetty, CK | 1 |
| Kumar, S | 1 |
| Khillan, V | 1 |
| Sarin, SK | 1 |
| Rusen, ID | 1 |
| Torrea, G | 1 |
| Phillips, PP | 1 |
| Squire, SB | 1 |
| Madan, J | 1 |
| Meredith, SK | 1 |
| Aung, KJ | 1 |
| Declercq, E | 1 |
| Sarker, MR | 1 |
| Das, PK | 1 |
| Rieder, HL | 3 |
| Harouna, SH | 1 |
| Boukary, I | 1 |
| Morou, S | 1 |
| Daouda, M | 1 |
| Hanki, Y | 1 |
| Cook, SV | 1 |
| Burgos, M | 1 |
| Yorke-Edwards, V | 1 |
| Anyo, G | 1 |
| Enarson, DA | 2 |
| Jindani, A | 1 |
| Lienhardt, C | 1 |
| Yamana, H | 1 |
| Matsui, H | 1 |
| Fushimi, K | 1 |
| Yasunaga, H | 1 |
| Xia, Q | 1 |
| Zhao, LL | 1 |
| Li, F | 1 |
| Fan, YM | 1 |
| Chen, YY | 1 |
| Wu, BB | 1 |
| Liu, ZW | 1 |
| Pan, AZ | 1 |
| Zhu, M | 1 |
| Symons, G | 1 |
| Venter, A | 2 |
| Donald, PR | 3 |
| van Niekerk, C | 2 |
| Hutchings, J | 1 |
| Schall, R | 2 |
| Franke, MF | 1 |
| Tierney, DB | 1 |
| Rich, ML | 1 |
| Bonilla, C | 1 |
| Bayona, J | 1 |
| McLaughlin, MM | 1 |
| Bhushan, B | 1 |
| Chander, R | 1 |
| Kajal, NC | 1 |
| Ranga, V | 1 |
| Gupta, A | 1 |
| Bharti, H | 1 |
| Mayor, S | 1 |
| Eisenach, K | 1 |
| Ive, P | 1 |
| Page-Shipp, L | 1 |
| Pym, A | 1 |
| Kuaban, C | 1 |
| Noeske, J | 1 |
| Aït-Khaled, N | 1 |
| Abena Foe, JL | 1 |
| Trébucq, A | 2 |
| Chakraborty, S | 1 |
| Rhee, KY | 1 |
| Alame-Emane, AK | 2 |
| Xu, P | 2 |
| Pierre-Audigier, C | 3 |
| Cadet-Daniel, V | 2 |
| Shen, X | 2 |
| Sraouia, M | 1 |
| Siawaya, JF | 1 |
| Takiff, H | 2 |
| Gao, Q | 2 |
| Gicquel, B | 4 |
| Shi, X | 1 |
| Li, C | 1 |
| Maslov, DA | 1 |
| Zaĭchikova, MV | 1 |
| Chernousova, LN | 1 |
| Shur, KV | 1 |
| Bekker, OB | 1 |
| Smirnova, TG | 1 |
| Larionova, EE | 1 |
| Andreevskaya, SN | 1 |
| Danilenko, VN | 1 |
| Verdugo, D | 1 |
| Fallows, D | 1 |
| Ahuja, S | 1 |
| Schluger, N | 1 |
| Kreiswirth, B | 1 |
| Mathema, B | 1 |
| Soeters, HM | 1 |
| York, T | 1 |
| Sampson, SL | 2 |
| Streicher, EM | 2 |
| van Helden, PD | 2 |
| Javaid, A | 2 |
| Basit, A | 1 |
| Afridi, AK | 1 |
| Khan, MA | 1 |
| Sulaiman, SA | 1 |
| Khan, AH | 2 |
| Wolfson, LJ | 1 |
| Gibbert, J | 1 |
| Wirth, D | 1 |
| Diel, R | 1 |
| Song, Y | 2 |
| Gu, Y | 1 |
| Yu, X | 1 |
| Jiang, G | 1 |
| Ma, Y | 2 |
| Gebhard, A | 1 |
| Gao, J | 1 |
| Du, J | 1 |
| Zhu, G | 2 |
| Tan, S | 1 |
| Fu, Y | 1 |
| Ma, L | 1 |
| Zhang, L | 1 |
| Hu, D | 1 |
| Lukoye, D | 1 |
| Kasule, GW | 1 |
| Musisi, K | 1 |
| Joloba, ML | 1 |
| Cobelens, FG | 1 |
| Luo, T | 1 |
| Nsofor, CA | 1 |
| Nguyen, L | 1 |
| Zheng, X | 2 |
| Zheng, R | 1 |
| Xu, B | 2 |
| Li, D | 1 |
| Drobniewski, F | 1 |
| Perkowski, E | 1 |
| Malik, S | 1 |
| Braunstein, MS | 1 |
| Zignol, M | 2 |
| Dean, AS | 1 |
| Alikhanova, N | 1 |
| Dadu, A | 1 |
| Driesen, M | 1 |
| Gilpin, C | 1 |
| Hasan, R | 1 |
| Hasan, Z | 1 |
| Husain, A | 1 |
| Hussain, A | 1 |
| Ismail, N | 1 |
| Kamal, M | 1 |
| Qadeer, E | 1 |
| Ruesch-Gerdes, S | 1 |
| Schito, M | 1 |
| Seyfaddinova, M | 1 |
| Wells, WA | 1 |
| Mukadi, YD | 1 |
| Kimerling, M | 1 |
| Floyd, K | 2 |
| Weyer, K | 2 |
| Raviglione, MC | 2 |
| Dolby, T | 1 |
| Simpson, JA | 1 |
| Prasad, R | 1 |
| Singh, A | 1 |
| Srivastava, R | 1 |
| Hosmane, GB | 1 |
| Kushwaha, RA | 1 |
| Jain, A | 1 |
| Huang, CC | 1 |
| Zhao, W | 1 |
| Zheng, M | 1 |
| Mu, X | 1 |
| Li, P | 1 |
| Liu, S | 1 |
| Guo, Z | 1 |
| McNaughton, A | 1 |
| Blackmore, T | 1 |
| McNaughton, H | 1 |
| Santra, G | 1 |
| Karak, A | 1 |
| Mukhopadhay, S | 1 |
| Dookie, N | 1 |
| Sturm, AW | 1 |
| Moodley, P | 1 |
| Tiberi, S | 1 |
| Fuentes, Z | 1 |
| Zumla, A | 1 |
| Sogebi, OA | 1 |
| Adefuye, BO | 1 |
| Adebola, SO | 1 |
| Oladeji, SM | 1 |
| Adedeji, TO | 1 |
| Zheng, Y | 1 |
| Fang, X | 1 |
| Piersimoni, C | 1 |
| Mustazzolu, A | 1 |
| Iacobino, A | 1 |
| Giannoni, F | 1 |
| Santoro, G | 1 |
| Gherardi, G | 1 |
| Del Giudice, A | 1 |
| Perna, R | 1 |
| Fattorini, L | 1 |
| Chen, L | 2 |
| Zhang, H | 1 |
| Thien, SJ | 1 |
| Krittaphol, W | 1 |
| Shaheen, Z | 1 |
| Weldegebreal, S | 1 |
| Mebrahtu, T | 1 |
| Murray, S | 1 |
| Mok, JH | 1 |
| Kang, BH | 1 |
| Lee, HK | 1 |
| Jang, HJ | 1 |
| Mphahlele, M | 1 |
| Syre, H | 1 |
| Valvatne, H | 1 |
| Stavrum, R | 1 |
| Mannsåker, T | 1 |
| Muthivhi, T | 1 |
| Grewal, HM | 2 |
| Senol, G | 1 |
| Coşkun, M | 1 |
| Gündüz, AT | 1 |
| Gayaf, M | 1 |
| Ozsöz, A | 1 |
| Doustdar, F | 1 |
| Khosravi, AD | 1 |
| Farnia, P | 1 |
| Oxlade, O | 1 |
| Schwartzman, K | 1 |
| Pai, M | 1 |
| Heymann, J | 1 |
| Royce, S | 1 |
| Rao, NA | 1 |
| Irfan, M | 1 |
| Soomro, MM | 1 |
| Mehfooz, Z | 1 |
| Volokhov, DV | 1 |
| Chizhikov, VE | 1 |
| Denkin, S | 1 |
| Napiórkowska, A | 1 |
| Augustynowicz-Kopeć, E | 1 |
| Zwolska, Z | 1 |
| Feasey, NA | 1 |
| Pond, M | 1 |
| Coleman, D | 1 |
| Solomon, AW | 1 |
| Cosgrove, CA | 1 |
| Delgado, R | 1 |
| Butcher, PD | 1 |
| Mitchison, DA | 3 |
| Harrison, T | 1 |
| Liang, Y | 1 |
| Zhang, J | 1 |
| Wang, L | 1 |
| Bai, X | 1 |
| Yu, Q | 1 |
| Li, N | 1 |
| Mohapatra, PR | 1 |
| Hari, DT | 1 |
| Joseph, P | 1 |
| Desai, VB | 1 |
| Mohan, NS | 1 |
| Fredrick, JS | 1 |
| Ramachandran, R | 2 |
| Raman, B | 1 |
| Wares, F | 1 |
| Thomas, A | 1 |
| Lee, WY | 1 |
| Ling, M | 1 |
| Anderson, G | 1 |
| Achawal, S | 1 |
| Thaker, HK | 1 |
| Whitney, J | 1 |
| Hurwitz, M | 1 |
| Mojtahed, A | 1 |
| Hwang, C | 1 |
| Gallo, A | 1 |
| Meek, C | 1 |
| Leff, R | 1 |
| Magis-Escurra, C | 1 |
| van den Boogaard, J | 1 |
| Ijdema, D | 1 |
| Boeree, M | 1 |
| Aarnoutse, R | 1 |
| Sturegård, E | 1 |
| Ängeby, K | 1 |
| Kwak, HK | 1 |
| Yun, YJ | 1 |
| Lee, MS | 1 |
| Min, SY | 1 |
| Park, SK | 2 |
| Kang, HS | 1 |
| Maeng, YH | 1 |
| Kook, YH | 1 |
| Lee, KH | 1 |
| Surcouf, C | 1 |
| Namouchi, A | 1 |
| Heng, S | 1 |
| Murray, A | 1 |
| Guillard, B | 1 |
| Williams, K | 1 |
| Minkowski, A | 1 |
| Amoabeng, O | 1 |
| Taylor, D | 1 |
| Andries, K | 1 |
| Wallis, RS | 1 |
| Yano, S | 1 |
| Kobayashi, K | 1 |
| Ikeda, T | 1 |
| Kant, S | 1 |
| Saheer, S | 1 |
| Hassan, G | 1 |
| Parengal, J | 1 |
| Leung, CC | 2 |
| Leung, EC | 2 |
| Leung, WM | 2 |
| Tam, CM | 2 |
| Gui, J | 1 |
| Lytras, T | 1 |
| Spala, G | 1 |
| Bonovas, S | 1 |
| Panagiotopoulos, T | 1 |
| Cuevas-Córdoba, B | 1 |
| Xochihua-González, SO | 1 |
| Cuellar, A | 1 |
| Fuentes-Domínguez, J | 1 |
| Zenteno-Cuevas, R | 1 |
| Papastavros, T | 1 |
| Dolovich, LR | 1 |
| Holbrook, A | 1 |
| Whitehead, L | 1 |
| Loeb, M | 1 |
| Rossetti, ML | 1 |
| Valim, AR | 1 |
| Silva, MS | 1 |
| Rodrigues, VS | 1 |
| Espinal, M | 1 |
| Danilova, ID | 1 |
| Punga, VV | 1 |
| Grzemska, M | 1 |
| Nolan, CM | 4 |
| Goldberg, SV | 1 |
| Pérez-Guzmán, C | 1 |
| Vargas, MH | 1 |
| Martínez-Rossier, LA | 1 |
| Torres-Cruz, A | 1 |
| Villarreal-Velarde, H | 1 |
| Phyu, S | 1 |
| Ti, T | 1 |
| Jureen, R | 1 |
| Hmun, T | 1 |
| Myint, H | 1 |
| Htun, A | 1 |
| Bjorvatn, B | 1 |
| Lu, PL | 1 |
| Lee, YW | 1 |
| Peng, CF | 1 |
| Tsai, JJ | 1 |
| Chen, YH | 1 |
| Hwang, KP | 1 |
| Chen, TP | 1 |
| Samman, Y | 2 |
| Krayem, A | 1 |
| Haidar, M | 1 |
| Mimesh, S | 1 |
| Osoba, A | 1 |
| Al-Mowaallad, A | 1 |
| Abdelaziz, M | 1 |
| Wali, S | 2 |
| Han, JP | 1 |
| Sun, SL | 1 |
| Li, RZ | 1 |
| Zhang, FS | 1 |
| Wang, SC | 1 |
| Cheng, J | 1 |
| Deng, YF | 1 |
| Yu, CB | 1 |
| Chulavatnatol, S | 1 |
| Chindavijak, B | 1 |
| Chierakul, N | 1 |
| Klomsawat, D | 1 |
| PETTY, TL | 1 |
| MITCHELL, RS | 1 |
| CORPE, RF | 1 |
| BLALOCK, FA | 1 |
| GROSS, JH | 1 |
| GOLDHAMMER, EJ | 1 |
| SCHLESS, JM | 1 |
| ALLISON, RF | 1 |
| INGLIS, RM | 1 |
| WHITE, EF | 1 |
| TOPPERMAN, S | 1 |
| Chen, QL | 1 |
| Yin, JJ | 1 |
| Saito, W | 1 |
| Nagayama, N | 1 |
| Miyamoto, M | 1 |
| Hara, H | 1 |
| Suzuki, J | 1 |
| Masuda, K | 1 |
| Baba, M | 1 |
| Tamura, A | 1 |
| Nagai, H | 1 |
| Akagawa, S | 1 |
| Kawabe, Y | 1 |
| Machida, K | 1 |
| Kurashima, A | 1 |
| Yotsumoto, H | 1 |
| Campos, PE | 1 |
| Suarez, PG | 1 |
| Sanchez, J | 1 |
| Zavala, D | 1 |
| Arevalo, J | 1 |
| Ticona, E | 1 |
| Hooton, TM | 1 |
| Holmes, KK | 1 |
| Lee, WC | 1 |
| Lee, DH | 1 |
| Han, L | 1 |
| Seung, KJ | 1 |
| Wade, MM | 1 |
| Volokhov, D | 1 |
| Peredelchuk, M | 1 |
| Chizhikov, V | 1 |
| Parsons, LM | 1 |
| Somoskövi, A | 2 |
| Urbanczik, R | 1 |
| Salfinger, M | 2 |
| Johansen, IS | 1 |
| Thomsen, VØ | 1 |
| Marjamäki, M | 1 |
| Sosnovskaja, A | 1 |
| Lundgren, B | 1 |
| Ward, HA | 1 |
| Marciniuk, DD | 1 |
| Hoeppner, VH | 1 |
| Jones, W | 1 |
| Rafailidis, PI | 1 |
| Avramopoulos, I | 1 |
| Sapkas, G | 1 |
| Falagas, ME | 1 |
| Younossian, AB | 1 |
| Rochat, T | 1 |
| Ketterer, JP | 1 |
| Wacker, J | 1 |
| Janssens, JP | 1 |
| Freier, G | 1 |
| Wright, A | 1 |
| Nelson, G | 1 |
| Brenner, E | 1 |
| Mase, S | 1 |
| Tasker, S | 1 |
| Matthews, KL | 1 |
| Bohnker, BK | 1 |
| Takashima, T | 1 |
| Danno, K | 1 |
| Tamura, Y | 1 |
| Nagai, T | 1 |
| Matsumoto, T | 1 |
| Han, Y | 1 |
| Ano, H | 1 |
| Yoshida, H | 1 |
| Kawahara, K | 1 |
| Tsuyuguchi, I | 1 |
| Moniruzzaman, A | 1 |
| Elwood, RK | 1 |
| Schulzer, M | 1 |
| FitzGerald, JM | 1 |
| Baquero-Artigao, F | 1 |
| Garcia-Miguel, MJ | 1 |
| Merino, R | 1 |
| García-Consuegra, J | 1 |
| del Castillo, F | 1 |
| Veziris, N | 1 |
| Aubry, A | 1 |
| Truffot-Pernot, C | 1 |
| Dormandy, J | 1 |
| Kreiswirth, BN | 1 |
| Driscoll, JR | 1 |
| Ashkin, D | 1 |
| Bai, GH | 1 |
| Choi, YW | 1 |
| Bai, JI | 1 |
| Martin, A | 1 |
| Cubillos-Ruiz, A | 1 |
| Von Groll, A | 1 |
| Del Portillo, P | 1 |
| Portaels, F | 2 |
| Palomino, JC | 1 |
| Sneag, DB | 1 |
| Cotton, MF | 1 |
| Zar, HJ | 1 |
| Suh, GY | 1 |
| Chung, MP | 1 |
| Kwon, OJ | 1 |
| Lim, SY | 2 |
| Kam, KM | 1 |
| Yip, CW | 1 |
| Ma, CH | 1 |
| Law, WS | 1 |
| Dhingra, VK | 1 |
| Rajpal, S | 1 |
| Mittal, A | 1 |
| Hanif, M | 1 |
| Piñeiro Pérez, R | 1 |
| Mellado Peña, MJ | 1 |
| Méndez Echevarría, A | 1 |
| Cilleruelo Ortega, MJ | 1 |
| García Hortelano, M | 1 |
| Villota Arrieta, J | 1 |
| Martín Fontelos, P | 1 |
| Sandblom, RE | 1 |
| Thummel, KE | 1 |
| Slattery, JT | 1 |
| Nelson, SD | 1 |
| Stevens, JP | 2 |
| Daniel, TM | 2 |
| Angarano, G | 1 |
| Carbonara, D | 1 |
| Costa, D | 1 |
| Passannante, MR | 1 |
| Gallagher, CT | 1 |
| Reichman, LB | 1 |
| Schrappe, M | 1 |
| Wassermann, K | 1 |
| Kroegel, C | 1 |
| Hill, AR | 1 |
| Mateo, F | 1 |
| Hudak, A | 1 |
| Horn, DL | 1 |
| Hewlett, D | 1 |
| Alfalla, C | 1 |
| Peterson, S | 1 |
| Opal, SM | 1 |
| Günthard, H | 1 |
| Fuhrer, HP | 1 |
| Pfyffer, GE | 2 |
| Ruef, C | 1 |
| Lüthy, R | 1 |
| Riley, LW | 1 |
| Chan, SP | 1 |
| Birnbaum, J | 1 |
| Rao, M | 1 |
| Steiner, P | 1 |
| Fisher, M | 1 |
| Tomlinson, DR | 1 |
| Coker, RJ | 1 |
| Botha, P | 1 |
| Beyers, N | 1 |
| Gie, RP | 1 |
| Vermeulen, HA | 1 |
| Groenewald, P | 1 |
| Coetzee, GJ | 1 |
| Hadiarto, M | 1 |
| Tjandra, YA | 1 |
| Hudoyo, A | 1 |
| de la Hoz, RE | 1 |
| Waycott, S | 1 |
| Garcia, D | 1 |
| Melendez, R | 1 |
| Bia, FJ | 1 |
| Colmenero, JD | 1 |
| García-Ordoñez, MA | 1 |
| Sebastián, MD | 1 |
| Pérez-Ruiz, E | 1 |
| Sánchez-Lora, J | 1 |
| Sánchez-González, J | 1 |
| Bentabol, G | 1 |
| Juárez, C | 1 |
| Blanco Ramos, JR | 1 |
| Rosel Rioja, L | 1 |
| Dopereiro Gómez, R | 1 |
| Oteo Revuelta, JA | 1 |
| Michałowska-Mitczuk, D | 2 |
| Kuś, J | 2 |
| Jouveshomme, S | 1 |
| Dautzenberg, B | 1 |
| Liu, Z | 1 |
| Shilkret, KL | 1 |
| Finelli, L | 1 |
| Coninx, R | 1 |
| Mathieu, C | 1 |
| Savina, D | 1 |
| Debacker, M | 1 |
| Jafarov, F | 1 |
| Jabrailov, I | 1 |
| Ismailov, A | 1 |
| Mirzoev, F | 1 |
| de Haller, R | 1 |
| Kimerling, ME | 1 |
| Phillips, P | 1 |
| Patterson, P | 1 |
| Hall, M | 1 |
| Robinson, CA | 1 |
| Dunlap, NE | 1 |
| Chang, AB | 1 |
| Grimwood, K | 1 |
| Harvey, AS | 1 |
| Rosenfeld, JV | 1 |
| Olinsky, A | 1 |
| Mehta, JB | 1 |
| Mejia, E | 1 |
| Gallemore, GH | 1 |
| Ramsey, GF | 1 |
| de Kantor, IN | 1 |
| Latini, O | 1 |
| Barrera, L | 1 |
| Rivera, AB | 1 |
| Tupasi, TE | 1 |
| Balagtas, ED | 1 |
| Cardano, RC | 1 |
| Baello, BQ | 1 |
| Quelapio, ID | 1 |
| Villa, LA | 1 |
| Pascual, LG | 1 |
| Co, VM | 1 |
| Mantala, MJ | 1 |
| Long, R | 1 |
| Scalcini, M | 1 |
| Gach, O | 1 |
| Corhay, JL | 1 |
| Lousberg, L | 1 |
| Bartsch, P | 1 |
| Ramaswamy, S | 1 |
| Musser, JM | 1 |
| Cheng, SJ | 1 |
| Thibert, L | 1 |
| Sanchez, T | 1 |
| Heifets, L | 1 |
| Taniguchi, H | 1 |
| Arnadottir, T | 1 |
| Khan, MY | 1 |
| Kinsara, AJ | 1 |
| Osoba, AO | 1 |
| Memish, Z | 1 |
| Bishop, KS | 1 |
| Blumberg, L | 1 |
| Trollip, AP | 1 |
| Smith, AN | 1 |
| Roux, L | 1 |
| York, DF | 1 |
| Kiepiela, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide During 8 Weeks of Treatment in Adult Subjects With Newly Diagnosed Drug-Sensitive or Mu[NCT02193776] | Phase 2 | 240 participants (Actual) | Interventional | 2014-10-23 | Completed | ||
| Refining Multidrug Tuberculosis Treatment With the Ultra Short All Oral Regimen[NCT03867136] | Phase 4 | 354 participants (Actual) | Interventional | 2020-06-01 | Active, not recruiting | ||
| Substitution of Ethambutol With Linezolid During the Intensive Phase of Treatment of Pulmonary Tuberculosis: A Prospective, Multicenter, Randomized, Open-label Phase II Trial[NCT01994460] | Phase 2 | 429 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Delamanid, Linezolid, Levofloxacin, and Pyrazinamide for the Treatment of Patients With Fluoroquinolone-sensitive MDR-TB: A Phase 2/3, Multicenter, Randomized, Open-label, Clinical Trial[NCT02619994] | Phase 2 | 238 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery[NCT00816426] | Phase 1 | 19 participants (Actual) | Interventional | 2008-12-29 | Completed | ||
| A Randomized Clinical Trial of Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa[NCT04618198] | Phase 3 | 436 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB[NCT05278988] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-04-01 | Recruiting | ||
| Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients[NCT03303963] | 3,356 participants (Actual) | Observational | 2017-05-04 | Completed | |||
| A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Plus PA-824 Plus Pyrazinamide Plus Clofazimine, TMC207 Plus PA-824 Plus Pyrazinamide, TMC207 Plus PA-824 Plus Clofazimine Alone, TMC207 Plus Pyra[NCT01691534] | Phase 2 | 105 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current So[NCT04062201] | Phase 3 | 402 participants (Actual) | Interventional | 2019-08-22 | Active, not recruiting | ||
| A Phase II Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 8 Weeks of Treatment in Adult Patients With Newly Diagnosed Drug-Sensitive or Multi D[NCT01498419] | Phase 2 | 207 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis[NCT04187469] | 286 participants (Anticipated) | Interventional | 2020-03-01 | Not yet recruiting | |||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277] | Phase 2 | 130 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
| TB Treatment Support Tools: Refinement and Evaluation of an Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes[NCT04221789] | 555 participants (Actual) | Interventional | 2020-11-17 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The bactericidal activity (BA) was determined by the rate of change in TTP collected from overnight sputum samples over 8 weeks of treatment in the liquid culture media MGIT system, represented by the model-fitted log(TTP) results as calculated by the regression of the observed log(TTP) results over time. The bactericidal activity of log(TTP) over Day 0 to Day 56 (BATTP[0-56]) was presented and expressed as the daily percentage change in TTP from Day 0 to Day 56. The mean BATTP (0-56) was calculated from Bayesian non-linear mixed effects regression models fitted to log(TTP) collected from sputum samples (observed from Day 0 to Day 56). (NCT02193776)
Timeframe: Day 0 to Day 56 (8 weeks)
| Intervention | percentage change in TTP/day (Mean) |
|---|---|
| DS-TB: Bedaquiline (Loading Dose/t.i.w)+ PA-824 + Pyrazinamide | 4.878 |
| DS-TB: Bedaquiline (200 mg) + PA-824 + Pyrazinamide | 5.182 |
| DS-TB: HRZE (Isoniazid+Rifampicin+Pyrazinamide+Ethambutol) | 4.046 |
| MDR-TB: Bedaquiline (200 mg)+Moxifloxacin+PA-824+Pyrazinamide | 5.194 |
A TEAE was defined as any AE which started or worsened on or after first study drug administration up to and including the Day 70 follow-up visit (or up to and including 14 days after last study drug administration for participants not having Day 70 follow-up visit). Drug-related TEAEs were defined as TEAEs for which relationship to study drug was indicated as 'possible', 'probable', 'certain' or missing. TEAEs leading to death were defined as TEAEs resulted 'fatal' outcome. Serious TEAEs were defined as TEAEs for which serious was indicated as 'yes'. TEAEs leading to discontinuation of study drug were defined as TEAEs for which action taken with study drug was indicated as 'study drug stopped'. TEAEs leading to early withdrawal from study were defined as TEAEs resulted study discontinuation. Grade III and IV TEAEs were defined as TEAEs for which severity (DMID grade) was indicated as 'Grade 3 (severe)' and 'Grade 4 (potentially life-threatening)' or missing, respectively. (NCT02193776)
Timeframe: First study drug administration (Day 1) up to and including the Day 70 follow-up visit (or up to and including 14 days after last study drug administration for participants not having the Day 70 follow-up visit) (70 days)
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | Drug-related TEAE | TEAE leading to death | Any serious TEAE | Drug-related serious TEAE | TEAE leading to discontinuation of study drug | TEAE leading to early withdrawal from study | Grade III TEAE | Grade IV TEAE | |
| DS-TB: Bedaquiline (200 mg) + PA-824 + Pyrazinamide | 45 | 29 | 1 | 3 | 0 | 5 | 5 | 17 | 7 |
| DS-TB: Bedaquiline (Loading Dose/t.i.w)+ PA-824 + Pyrazinamide | 50 | 38 | 1 | 4 | 2 | 6 | 5 | 19 | 8 |
| DS-TB: HRZE (Isoniazid+Rifampicin+Pyrazinamide+Ethambutol) | 44 | 29 | 1 | 4 | 1 | 2 | 2 | 14 | 2 |
| MDR-TB: Bedaquiline (200 mg)+Moxifloxacin+PA-824+Pyrazinamide | 57 | 46 | 0 | 4 | 2 | 2 | 2 | 13 | 1 |
(NCT01691534)
Timeframe: 14 consecutive days of treatment
| Intervention | log10CFU/ml/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 0.115 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 0.167 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 0.076 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 0.124 |
| Pyrazinamide (Z) | 0.036 |
| Clofazimine (C) | -0.017 |
| Rifafour | 0.151 |
(NCT01691534)
Timeframe: Days 0-14
| Intervention | percentage of change in time/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 6.3 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 7.0 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 4.3 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 4.9 |
| Pyrazinamide (Z) | 2.0 |
| Clofazimine (C) | -0.3 |
| Rifafour | 6.3 |
(NCT01691534)
Timeframe: Day 0-2
| Intervention | percentage of change in time/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 10.6 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 13.2 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 6.0 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 9.1 |
| Pyrazinamide (Z) | 4.7 |
| Clofazimine (C) | 2.1 |
| Rifafour | 12.9 |
(NCT01691534)
Timeframe: Days 7-14
| Intervention | percentage of change in time/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 3.6 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 4.5 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 3.1 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 3.0 |
| Pyrazinamide (Z) | 0.8 |
| Clofazimine (C) | -1.3 |
| Rifafour | 4.4 |
(NCT01691534)
Timeframe: Days 0-2
| Intervention | log10CFU/ml/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 0.161 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 0.196 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 0.062 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 0.132 |
| Pyrazinamide (Z) | 0.080 |
| Clofazimine (C) | 0.018 |
| Rifafour | 0.141 |
(NCT01691534)
Timeframe: Day 7-14
| Intervention | log10CFU/ml/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 0.085 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 0.146 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 0.085 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 0.118 |
| Pyrazinamide (Z) | 0.022 |
| Clofazimine (C) | -0.038 |
| Rifafour | 0.157 |
(NCT01498419)
Timeframe: 8 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 13 |
| Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 19 |
| Drug Sensitive: Rifafour | 12 |
| Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 12 |
Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB. This was measured at visit 24(Day 57). (NCT01498419)
Timeframe: Day 57 after eight weeks of daily treatment
| Intervention | percentage of patients (Number) |
|---|---|
| Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 65.7 |
| Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 71.4 |
| Drug Sensitive: Rifafour | 37.8 |
| Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 50.0 |
Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB. (Day 57) (NCT01498419)
Timeframe: Day 57 after eight weeks of daily treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 82.9 |
| Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 94.3 |
| Drug Sensitive: Rifafour | 87.5 |
| Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 62.5 |
The primary efficacy endpoint was bactericidal activity characterized by the daily rate of change in mean log10CFU counts during 8 weeks of treatment (bactericidal activity assessed by CFU on solid media for days 0-56). (NCT01498419)
Timeframe: 8 weeks
| Intervention | log10CFU/ml/day (Mean) |
|---|---|
| Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 0.133 |
| Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 0.155 |
| Drug Sensitive: Rifafour | 0.112 |
| Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 0.117 |
Measurement of TTP in liquid culture media Mycobacteria growth indicator tube (MGIT) using standard procedures (NCT01498419)
Timeframe: 8 weeks
| Intervention | log10hours/day (Mean) |
|---|---|
| Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 0.020 |
| Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 0.020 |
| Drug Sensitive: Rifafour | 0.017 |
| Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 0.015 |
liquid culture = Mycobacteria growth indicator tube (MGIT) Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB (NCT01498419)
Timeframe: 8 weeks
| Intervention | days (Median) |
|---|---|
| Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 42.0 |
| Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 49.0 |
| Drug Sensitive: Rifafour | 56.0 |
| Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 56.0 |
Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB (NCT01498419)
Timeframe: 8 weeks
| Intervention | days (Median) |
|---|---|
| Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 28.0 |
| Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 28.0 |
| Drug Sensitive: Rifafour | 35.0 |
| Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 35.0 |
30 reviews available for pyrazinamide and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Isoniazid derivatives and their anti-tubercular activity.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Isoniazid; Mycobacterium tuberculosis; Tuber | 2017 |
Anti-Tubercular Activity of Pyrazinamide Conjugates: Synthesis and Structure-Activity Relationship Studies.
Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Pyrazinamide; Structure-Activity Relation | 2023 |
Evidence for Implementation: Management of TB in HIV and Pregnancy.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmiss | 2022 |
Global status of phenotypic pyrazinamide resistance in
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sens | 2023 |
[Treatment of tuberculosis: what is new?]
Topics: Antitubercular Agents; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Tuberculosis; Tuberculosis, Mu | 2023 |
The Bewildering Antitubercular Action of Pyrazinamide.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Development; Drug Resistance, Multipl | 2020 |
Tuberculosis treatment in children: The changing landscape.
Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Humans; Is | 2020 |
Tuberculosis in 2019.
Topics: Antitubercular Agents; Ethambutol; Health Policy; Humans; India; Isoniazid; Molecular Diagnostic Tec | 2020 |
Pretomanid for tuberculosis: a systematic review.
Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Co | 2022 |
Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Disease Progression; Drug Resistance, Multiple, Bacter | 2017 |
Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era.
Topics: Animals; Antitubercular Agents; Bacteriological Techniques; Drug Resistance, Multiple, Bacterial; Ge | 2017 |
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Antibiotics, Antitubercular; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination | 2018 |
Development of new drug-regimens against multidrug-resistant tuberculosis.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Development; Drug Therapy, Combination; Du | 2019 |
Managing multidrug-resistant tuberculosis in children: review of recent developments.
Topics: Antitubercular Agents; Child; Child, Preschool; Directly Observed Therapy; Drug Administration Sched | 2014 |
Antitubercular therapy in patients with cirrhosis: challenges and options.
Topics: Antitubercular Agents; Ethambutol; Humans; Immune System Diseases; Isoniazid; Latent Tuberculosis; L | 2014 |
Drug resistance in Mycobacterium tuberculosis: molecular mechanisms challenging fluoroquinolones and pyrazinamide effectiveness.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Mycobacterium tuberculo | 2015 |
Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.
Topics: Antitubercular Agents; Diarylquinolines; Drug Design; Drug Resistance, Bacterial; Drug Therapy, Comb | 2015 |
A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis.
Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Pyrazinamide; Tuberculosis, Multidrug-Res | 2015 |
Clinical research in the treatment of tuberculosis: current status and future prospects.
Topics: Antitubercular Agents; Biomedical Research; Clinical Trials as Topic; Drug Therapy, Combination; Flu | 2015 |
Antibiotic resistance mechanisms in M. tuberculosis: an update.
Topics: Aminosalicylic Acid; Antibiotics, Antitubercular; Antitubercular Agents; Drug Resistance, Multiple, | 2016 |
Anti-tuberculosis drug resistance in Ethiopia: systematic review.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethiopia; Humans; Isoniazid | 2017 |
[Advances in the research of rapid detection methods of pyrazinamide-resistant Mycobacterium tuberculosis].
Topics: Antitubercular Agents; Microbiological Techniques; Mycobacterium tuberculosis; Pyrazinamide; Tubercu | 2012 |
[Resistant tuberculosis: a molecular review].
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; Humans; Isoniazid; Mycobact | 2002 |
Laboratory diagnostic aspects of drug resistant tuberculosis.
Topics: Animals; Antitubercular Agents; Bacteriophages; Clinical Laboratory Techniques; Drug Resistance, Bac | 2004 |
[Trends in tuberculosis treatment duration].
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Resistance | 2006 |
Advances in the treatment of tuberculosis.
Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Ag | 2007 |
Multidrug-resistant tuberculosis in the USA: the end of the beginning.
Topics: Antitubercular Agents; BCG Vaccine; Ciprofloxacin; Health Personnel; Humans; Pyrazinamide; Tuberculo | 1996 |
[Antitubercular chemotherapy].
Topics: Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Protocols; Drug | 1997 |
Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Cy | 1998 |
[Molecular mechanisms of multidrug resistance in Mycobacterium tuberculosis].
Topics: Antitubercular Agents; Drug Resistance, Multiple; Ethambutol; Humans; Isoniazid; Mutation; Mycobacte | 2000 |
20 trials available for pyrazinamide and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in So
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Li | 2022 |
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in So
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Li | 2022 |
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in So
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Li | 2022 |
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in So
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Li | 2022 |
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Et | 2023 |
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Hu | 2019 |
Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients.
Topics: Adult; Antitubercular Agents; Bacterial Load; Clofazimine; Dose-Response Relationship, Drug; Drug De | 2020 |
Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Protocols; DNA, Bacterial; Female; Fluoroqu | 2021 |
A highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis: a multicenter prospective study in China.
Topics: Antitubercular Agents; China; Humans; Mycobacterium tuberculosis; Prospective Studies; Pyrazinamide; | 2021 |
Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Substitution; Drug Therapy, Combination; | 2019 |
Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.
Topics: Adolescent; Adult; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, Combination; Etha | 2018 |
Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study.
Topics: Adult; Amidohydrolases; Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Female; | 2019 |
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical | 2019 |
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
Topics: Antitubercular Agents; Computer Simulation; Diarylquinolines; Double-Blind Method; Drug Therapy, Com | 2019 |
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.
Topics: Antitubercular Agents; Bangladesh; Clinical Protocols; Clofazimine; Drug Administration Schedule; Dr | 2014 |
Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis.
Topics: Africa; Antitubercular Agents; Asia; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol | 2014 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul
Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethamb | 2015 |
Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India.
Topics: Adult; Antibiotics, Antitubercular; Communicable Disease Control; Cycloserine; Directly Observed The | 2011 |
Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; | 2002 |
Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis.
Topics: Health Personnel; Humans; Occupational Diseases; Ofloxacin; Premedication; Pyrazinamide; Tuberculosi | 1994 |
Treatment of multidrug-resistant tuberculosis in Indonesia.
Topics: Adult; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Indonesia; Isoniazid; M | 1996 |
[Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Child; Chi | 1997 |
244 other studies available for pyrazinamide and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Bacterial Proteins; DNA Mutational Analysis; Mutation; Mycob | 2008 |
New fluorine-containing hydrazones active against MDR-tuberculosis.
Topics: Animals; Antitubercular Agents; Cell Line; Fluorine; Humans; Hydrazones; Microbial Sensitivity Tests | 2011 |
Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China.
Topics: Antitubercular Agents; Drug Resistance; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sens | 2022 |
The pncA gene mutations of Mycobacterium tuberculosis in multidrug-resistant tuberculosis.
Topics: Adult; Alanine; Amidohydrolases; Antitubercular Agents; Aspartic Acid; Bacterial Proteins; Codon; Cr | 2022 |
Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Genomics; Humans; Microbial Sensitivity Tests; Mutation; Myc | 2022 |
High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB.
Topics: Antitubercular Agents; Gatifloxacin; Humans; Isoniazid; Pyrazinamide; Treatment Outcome; Tuberculosi | 2022 |
Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South Korea.
Topics: Antitubercular Agents; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Prothionamide; Pyrazin | 2022 |
[Investigation of pncA, rpsA and panD Gene Mutations Associated with Resistance in Pyrazinamide-Resistant Mycobacterium tuberculosis Isolates and Spoligotyping].
Topics: Antitubercular Agents; Humans; Mutation; Mycobacterium tuberculosis; Pyrazinamide; Tuberculosis; Tub | 2022 |
Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant
Topics: Anti-Bacterial Agents; Antitubercular Agents; Ethambutol; Humans; Levofloxacin; Linezolid; Mycobacte | 2023 |
Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
Topics: Adult; Antitubercular Agents; Clofazimine; Humans; Microbial Sensitivity Tests; Mycobacterium tuberc | 2023 |
Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Isoniazid; Li | 2022 |
Prediction of drug resistance by Sanger sequencing of Mycobacterium tuberculosis complex strains isolated from multidrug resistant tuberculosis suspect patients in Ethiopia.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethiopia; Humans; Isoniazid | 2022 |
Comparison of different regimens with or without fluoroquinolone in isoniazid-resistant tuberculosis: A multicenter cohort study.
Topics: Antitubercular Agents; Cohort Studies; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Huma | 2022 |
Pyrazinamide resistance in rifampicin discordant tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mutation; Mycobacterium tuber | 2022 |
In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Genotype; Humans; Isoniazid; Levofloxacin; Microbial S | 2022 |
Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberc | 2022 |
Pyrazinamide-resistant Tuberculosis Obscured From Common Targeted Molecular Diagnostics.
Topics: Amidohydrolases; Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium | 2023 |
Quantitative
Topics: Amidohydrolases; Antitubercular Agents; Humans; Magnetic Resonance Spectroscopy; Microbial Sensitivi | 2023 |
Acquired drug resistance during the turnaround time for drug susceptibility testing impacts outcome of tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; P | 2023 |
Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; My | 2023 |
Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure.
Topics: Amikacin; Antitubercular Agents; Humans; Isoniazid; Linezolid; Microbial Sensitivity Tests; Moxiflox | 2023 |
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Markov Chains; Nitroimidazoles; Prevalence; | 2019 |
Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
Topics: A549 Cells; Administration, Inhalation; Aerosols; Antitubercular Agents; Cell Line; Cell Line, Tumor | 2019 |
[Tuberculosis].
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Mycobacterium tuberculosis; Pyrazinamide; Rifa | 2019 |
Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Topics: Adult; Age Factors; Amidohydrolases; Antitubercular Agents; Base Sequence; China; Diarylquinolines; | 2020 |
Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France.
Topics: Antitubercular Agents; Bacterial Proteins; DNA-Directed RNA Polymerases; Drug Resistance, Multiple, | 2020 |
Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Cycloserine; Extensively Drug-Resistant Tuberculosis; Female; Humans; | 2020 |
Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility.
Topics: Adult; Antitubercular Agents; Female; Humans; Male; Microbial Sensitivity Tests; Mycobacterium tuber | 2020 |
High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.
Topics: Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2020 |
Reply to Decroo
Topics: Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2020 |
High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sens | 2020 |
Survey of drug resistance associated gene mutations in Mycobacterium tuberculosis, ESKAPE and other bacterial species.
Topics: Antitubercular Agents; Bacterial Proteins; Data Curation; Databases, Genetic; DNA, Bacterial; Drug R | 2020 |
How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide.
Topics: Amidohydrolases; Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium | 2020 |
Gitelman-like syndrome: A rare complication of using aminoglycosides in tuberculosis - A case report.
Topics: Alkalosis; Antitubercular Agents; Capreomycin; Clofazimine; Cycloserine; Deprescriptions; Ethionamid | 2020 |
Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Bangladesh; Child; Child, Preschool; Clinical Protoc | 2020 |
Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Bacterial; Epide | 2020 |
Management of isoniazid-monoresistant tuberculosis (Hr-TB) in Queensland, Australia: a retrospective case series.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Australia; Child; Child, Preschoo | 2020 |
Genotypic Resistance of Pyrazinamide but Not Minimum Inhibitory Concentration Is Associated With Longer Time to Sputum Culture Conversion in Patients With Multidrug-resistant Tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Cohort Studies; Humans; Microbial Sensitivity Tests; Mutatio | 2021 |
Pyrazinamide resistance and pncA mutations in drug resistant Mycobacterium tuberculosis clinical isolates from Myanmar.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; DNA Mutational Analysis; DNA, Bac | 2020 |
Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review.
Topics: Adult; Amikacin; Antitubercular Agents; Clofazimine; Drug Administration Schedule; Drug Resistance, | 2021 |
Five-year microevolution of a multidrug-resistant Mycobacterium tuberculosis strain within a patient with inadequate compliance to treatment.
Topics: Adult; Antitubercular Agents; Argentina; Drug Resistance, Multiple, Bacterial; Female; Humans; Isoni | 2021 |
Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.
Topics: Adult; Aged; Aged, 80 and over; Amidohydrolases; Antitubercular Agents; Beijing; China; DNA, Bacteri | 2021 |
Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Te | 2021 |
Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
Topics: Adult; Antitubercular Agents; Brazil; Clofazimine; Drug Therapy, Combination; Female; Humans; Logist | 2017 |
The Rate of Drug-Resistant Tuberculosis in Korean Children and Adolescents Since 2007.
Topics: Adolescent; Antitubercular Agents; Asian People; Child; Child, Preschool; Drug Resistance, Multiple, | 2017 |
Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment.
Topics: Amidohydrolases; Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium | 2017 |
Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment".
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide | 2017 |
Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Combinations; Ethambutol; HIV Infections | 2017 |
Pyrazinamide Susceptibility and
Topics: Adolescent; Adult; Amidohydrolases; Antitubercular Agents; Bangladesh; Child; Child, Preschool; Drug | 2017 |
Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.
Topics: Amidohydrolases; Antitubercular Agents; Genotype; Georgia (Republic); Humans; Microbial Sensitivity | 2017 |
Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cohort Studies; Drug Resistance, Bacterial; Female; | 2017 |
pH Conditions under Which Pyrazinamide Works in Humans.
Topics: Antitubercular Agents; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Mycobacteriu | 2017 |
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Topics: Adult; Age Distribution; Aged; Alcohol Drinking; Aminosalicylic Acid; Antitubercular Agents; Cohort | 2017 |
Detection of
Topics: Antitubercular Agents; Bacterial Proteins; Biological Assay; Drug Resistance, Bacterial; Humans; Mic | 2018 |
Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit.
Topics: Adult; Aged; Antitubercular Agents; Asian People; China; Clinical Audit; Ethambutol; Female; Fluoroq | 2017 |
Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
Topics: Adult; Aged; Amidohydrolases; Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Fe | 2017 |
Secretome profile analysis of multidrug-resistant, monodrug-resistant and drug-susceptible Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; Gene Expression Profiling; | 2018 |
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Child; Drug Administration Schedule; Drug Combinations; Drug | 2018 |
Outcomes of pulmonary tuberculosis in patients with discordant phenotypic isoniazid resistance testing.
Topics: Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Fema | 2017 |
Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data.
Topics: Antitubercular Agents; Ciprofloxacin; Ethambutol; Humans; Isoniazid; Machine Learning; Microbial Sen | 2018 |
Pyrazinamide Resistance among Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Myanmar.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gene | 2018 |
Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide | 2018 |
Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China.
Topics: Amidohydrolases; Antitubercular Agents; Bacterial Proteins; Carboxy-Lyases; China; Genotype; Humans; | 2018 |
Molecular Screening Versus Phenotypic Susceptibility Testing of Multidrug-Resistant Mycobacterium tuberculosis Isolates for Streptomycin and Ethambutol.
Topics: Antitubercular Agents; Ethambutol; Genes, Bacterial; Microbial Sensitivity Tests; Mutation; Mycobact | 2018 |
Drug resistant tuberculosis in Saudi Arabia: an analysis of surveillance data 2014-2015.
Topics: Adult; Age Factors; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Logistic Models; M | 2018 |
Analysis of mutations in pncA reveals non-overlapping patterns among various lineages of Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Cell Lineage; Humans; Microbial Sensitivity Tests; Mutation; | 2018 |
Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia.
Topics: Amidohydrolases; Antitubercular Agents; DNA Mutational Analysis; Drug Resistance, Multiple, Bacteria | 2018 |
Prevalence of Pyrazinamide Resistance in Khyber Pakhtunkhwa, Pakistan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Child, Preschool; Female; | 2018 |
[Management and treatment difficulties of multi-drug resistant pulmonary tuberculosis in a pediatric case].
Topics: Adult; Antitubercular Agents; Female; Humans; Infant; Isoniazid; Mycobacterium tuberculosis; Pyrazin | 2018 |
Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan.
Topics: Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Female; Humans; Logistic Models; | 2018 |
Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Cross-Sectional Studies; Extensively Drug-Res | 2018 |
Analysis of a Novel pncA Mutation for Susceptibility to Pyrazinamide Therapy.
Topics: Adult; Amidohydrolases; Antitubercular Agents; Female; Humans; Mutation; Pyrazinamide; Sequence Anal | 2018 |
Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.
Topics: Algorithms; Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Monte Carlo Metho | 2018 |
Is sequencing better than phenotypic tests for the detection of pyrazinamide resistance?
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Te | 2018 |
Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
Topics: Antitubercular Agents; Ethambutol; Ethiopia; Female; HIV Infections; Humans; Isoniazid; Male; Mycoba | 2018 |
Characterization of pncA mutations in multi-drug and pyrazinamide resistant Mycobacterium tuberculosis isolates cultured from Queensland migrants and Papua New Guinea residents.
Topics: Amidohydrolases; Antitubercular Agents; Black People; DNA Mutational Analysis; DNA, Bacterial; Drug | 2018 |
Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis.
Topics: Adjuvants, Immunologic; Anti-Bacterial Agents; Antitubercular Agents; Cell Line; Drug Therapy, Combi | 2018 |
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Topics: Adult; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Resistance, Multiple, Bacterial; E | 2019 |
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Topics: Antitubercular Agents; Clofazimine; Colony Count, Microbial; Computer Simulation; Diarylquinolines; | 2018 |
Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis.
Topics: Aerosols; Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Therapy, Comb | 2018 |
pncA gene mutations in reporting pyrazinamide resistance among the MDR-TB suspects.
Topics: Amidohydrolases; Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Humans; Microbi | 2019 |
Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
Topics: Adolescent; Adult; Antitubercular Agents; Cohort Studies; Drug Resistance, Multiple, Bacterial; Fema | 2019 |
Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethiona | 2019 |
Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; DNA-Directed RNA Polymerases; Drug Resistance, Multiple, | 2019 |
Population Pharmacokinetic Modelling of Pyrazinamide and Pyrazinoic Acid in Patients with Multi-Drug Resistant Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Chromatography, Liquid; Female; Humans; Male; Middle Aged; | 2019 |
Isoniazid-Resistant Rifampicin-Susceptible Tuberculosis in Children.
Topics: Antitubercular Agents; Child; Child, Preschool; Contact Tracing; Drug Resistance, Multiple, Bacteria | 2019 |
Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.
Topics: Adult; Amidohydrolases; Antitubercular Agents; Female; Humans; Male; Microbial Sensitivity Tests; Mi | 2019 |
Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; DNA, Bacterial; Eswatini; Genotype; Humans; Microarray Analy | 2019 |
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
Topics: Adult; Antitubercular Agents; Decision Support Techniques; Disease Progression; Drug Administration | 2019 |
First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Multiple, Bacter | 2019 |
Drug-Induced Fulminant Hepatitis in a Child Treated for Latent Multidrug-Resistant Tuberculosis With Dual Therapy Combining Pyrazinamide and Levofloxacin.
Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Humans; Latent Tuberculosis; Levofloxacin; | 2019 |
Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015.
Topics: Adult; Aged; Antitubercular Agents; Ethambutol; Humans; Incidence; Isoniazid; Logistic Models; Middl | 2019 |
Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Duration of Therapy; Etha | 2019 |
Isoniazid- and streptomycin-resistant miliary tuberculosis complicated by intracranial tuberculoma in a Japanese infant.
Topics: Antitubercular Agents; Drug Substitution; Drug Therapy, Combination; Ethambutol; Ethionamide; Female | 2013 |
Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea.
Topics: Acetyltransferases; Amidohydrolases; Amikacin; Antigens, Bacterial; Bacterial Proteins; Capreomycin; | 2013 |
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
Topics: Animals; Antitubercular Agents; Area Under Curve; Disease Models, Animal; Drug Evaluation, Preclinic | 2013 |
Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Bacterial; | 2013 |
[Detection of pncA mutation associated with pyrazinamide resistance in Mycobacterium tuberculosis by high-resolution melting cure analysis].
Topics: Amidohydrolases; Antitubercular Agents; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Gen | 2013 |
Pyrazinamide resistance among drug-resistant Mycobacterium tuberculosis isolates at a referral hospital.
Topics: Antitubercular Agents; Cross Infection; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Te | 2013 |
Rapid detection of pyrazinamide resistant Mycobacterium tuberculosis by high resolution melting curve analysis.
Topics: Antitubercular Agents; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Mutation; My | 2013 |
Clonal expansion of Mycobacterium tuberculosis isolates and coexisting drug resistance in patients newly diagnosed with pulmonary tuberculosis in Hanoi, Vietnam.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clone Cells; DNA, Bacterial; Drug | 2013 |
Pyrazinamide susceptibility testing of Mycobacterium tuberculosis by high resolution melt analysis.
Topics: Adolescent; Adult; Aged; Amidohydrolases; Antitubercular Agents; Child; Child, Preschool; Drug Resis | 2014 |
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolon | 2014 |
Next-generation sequencing for identifying pyrazinamide resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Female; Humans; Male; Mycobacterium tuberculosis; Pyrazinamide; Tuberculosis, | 2014 |
Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis.
Topics: Adolescent; Antibiotic Prophylaxis; Antitubercular Agents; Child; Contact Tracing; Humans; Latent Tu | 2014 |
Multidrug-resistant tuberculosis in Western Australia, 1998-2012.
Topics: Adolescent; Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Child; Drug Therapy, | 2014 |
Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California.
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide | 2014 |
Cervical lymphadenopathy--pitfalls of blind antitubercular treatment.
Topics: Adolescent; Adult; Antitubercular Agents; Biopsy; Diagnostic Errors; Ethambutol; Female; Histiocytic | 2014 |
Association between pncA gene mutations, pyrazinamidase activity, and pyrazinamide susceptibility testing in Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Te | 2014 |
Genetic diversity within Mycobacterium tuberculosis complex impacts on the accuracy of genotypic pyrazinamide drug-susceptibility assay.
Topics: Amidohydrolases; Antitubercular Agents; Female; Humans; Male; Mycobacterium tuberculosis; Pyrazinami | 2014 |
Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm.
Topics: Adult; Algorithms; Amidohydrolases; Antitubercular Agents; Bacterial Proteins; DNA Mutational Analys | 2014 |
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bangladesh; Child; Clofazimine; Dose-Response Relati | 2014 |
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bangladesh; Child; Clofazimine; Dose-Response Relati | 2014 |
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bangladesh; Child; Clofazimine; Dose-Response Relati | 2014 |
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bangladesh; Child; Clofazimine; Dose-Response Relati | 2014 |
High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Clofazimine; Dose-Response Relationship, Drug | 2014 |
Treatment options and outcomes of hospitalised tuberculosis patients: a nationwide study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Child, Preschool; Ethambut | 2015 |
Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bacterial Proteins; China; DNA, B | 2015 |
Counting pyrazinamide in regimens for multidrug-resistant tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Female; Follow-Up Studies; Humans; Male; Mycobacterium tuberculo | 2015 |
Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Arthralgia; Ataxia; Chemical and Drug Induced Liver | 2014 |
New drug combination may shorten tuberculosis treatment, study says.
Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Nitroimidazoles; Pyrazinamide; Tuberc | 2015 |
New effective antituberculosis regimens.
Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Nitroimidazoles; Pyrazi | 2015 |
High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cameroon; Clofazimine; Cohort Studies; Confidence In | 2015 |
Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance.
Topics: Amidohydrolases; Antitubercular Agents; China; DNA Mutational Analysis; DNA, Bacterial; Drug Resista | 2015 |
The indirect microscopic observation drug susceptibility assay demonstrated high concordance with the indirect MGIT method for pyrazinamide susceptibility testing.
Topics: Amidohydrolases; Antitubercular Agents; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Microbia | 2015 |
Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: pncA sequencing versus Bactec MGIT 960.
Topics: Amidohydrolases; Antitubercular Agents; Bacteriological Techniques; DNA Mutational Analysis; Drug Re | 2015 |
Epidemiologic Correlates of Pyrazinamide-Resistant Mycobacterium tuberculosis in New York City.
Topics: Adult; Antitubercular Agents; Female; Genotype; Humans; Male; Middle Aged; Mycobacterium tuberculosi | 2015 |
Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance.
Topics: Adolescent; Adult; Antitubercular Agents; Cohort Studies; Drug Administration Schedule; Drug Resista | 2015 |
Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
Topics: Antitubercular Agents; Computer Simulation; Cost-Benefit Analysis; Diarylquinolines; Drug Costs; Dru | 2015 |
Pyrazinamide resistance determined by liquid culture at low pH better correlates with genetic mutations in MDR tuberculosis isolates.
Topics: Antitubercular Agents; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Mycobacterium tuberc | 2015 |
Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations.
Topics: Adult; Aged; Amino Acid Substitution; Antitubercular Agents; China; Codon; Drug Resistance, Bacteria | 2016 |
No evidence that pyrazinamide resistance is acquired after fluoroquinolone resistance.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Mycobacterium | 2016 |
In reply.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Mycobacterium | 2016 |
Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; China; Cohort Studies; Drug Resistance, Bacterial; Drug Th | 2016 |
Whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda.
Topics: Adult; Antitubercular Agents; Bacterial Proteins; Female; Genome, Bacterial; Humans; Male; Microbial | 2016 |
Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.
Topics: Adult; Amidohydrolases; Antitubercular Agents; China; DNA Mutational Analysis; Drug Resistance, Mult | 2016 |
Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
Topics: Adolescent; Adult; Aged; Amikacin; Antitubercular Agents; China; Drug Therapy, Combination; Female; | 2016 |
Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.
Topics: Adult; Age Factors; Aged; Amidohydrolases; Antitubercular Agents; China; Codon; Cross-Sectional Stud | 2016 |
Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.
Topics: Administration, Inhalation; Aerosols; Animals; Antitubercular Agents; Esters; Guinea Pigs; Male; Mic | 2016 |
Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.
Topics: Anti-Infective Agents; Antitubercular Agents; Asia; Fluoroquinolones; Humans; Microbial Sensitivity | 2016 |
Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Genotype; Humans; Microbial Sensitivity | 2016 |
Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Cohort Studies; Cycloserine; Drug Therapy, Combination; Ethambutol; Et | 2016 |
Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Amidohydrolases; Antitubercular Agents; Biological | 2016 |
Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
Topics: Aminosalicylic Acid; Animals; Antitubercular Agents; Capreomycin; Drug Combinations; Drug Interactio | 2016 |
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Cl | 2016 |
Gitelman-like Syndrome with Kanamycin Toxicity.
Topics: Adult; Alkalosis; Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fl | 2016 |
Mechanisms of first-line antimicrobial resistance in multi-drug and extensively drug resistant strains of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa.
Topics: Amidohydrolases; Antitubercular Agents; Bacterial Proteins; Catalase; Drug Resistance, Multiple, Bac | 2016 |
Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Drug Therapy, Combination; Ethambutol; | 2017 |
Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
Topics: Adult; Age Factors; Aminoglycosides; Antitubercular Agents; Audiometry, Pure-Tone; Body Mass Index; | 2017 |
Genotyping and Prevalence of Pyrazinamide- and Moxifloxacin-Resistant Tuberculosis in China, 2000 to 2010.
Topics: Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Micr | 2017 |
Pyrazinamide susceptibility testing: proposed new standard with the BACTECTM MGITTM 960 system.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sens | 2016 |
Resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity T | 2017 |
Resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones - Authors' reply.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity T | 2017 |
Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis.
Topics: Administration, Inhalation; Antitubercular Agents; Chemistry, Pharmaceutical; Chromatography, High P | 2017 |
Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.
Topics: Adult; Antitubercular Agents; Communicable Disease Control; Drug Administration Schedule; Ethambutol | 2017 |
TB Alliance regimen development for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Etham | 2016 |
Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Multiple, | 2017 |
Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amidohydrolases; Amino Acid Substitution; Antitubercular | 2008 |
[Investigation of pyrazinamide resistance in multidrug-resistant tuberculosis cases in Hospital of Pulmonary Diseases, Izmir, Turkey].
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide | 2008 |
Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran.
Topics: Amidohydrolases; Antitubercular Agents; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Genoty | 2009 |
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.
Topics: Antitubercular Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacteri | 2010 |
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis.
Topics: Cohort Studies; Communicable Disease Control; Drug Resistance, Bacterial; Global Health; HIV Infecti | 2010 |
Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients.
Topics: Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Female; | 2010 |
Molecular detection of drug-resistant Mycobacterium tuberculosis with a scanning-frame oligonucleotide microarray.
Topics: Amidohydrolases; Antitubercular Agents; Humans; Mutation; Mycobacterium tuberculosis; Oligonucleotid | 2009 |
[Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Ison | 2010 |
Moxifloxacin and pyrazinamide susceptibility testing in a complex case of multidrug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Fluoroquinolones; Humans; Ma | 2011 |
Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs.
Topics: Acyltransferases; Animals; Antigens, Bacterial; Antitubercular Agents; Colony Count, Microbial; Comb | 2011 |
Predicting outcomes and drug resistance with new standardised treatment.
Topics: Cohort Studies; Communicable Disease Control; Drug Resistance, Bacterial; Global Health; Humans; Iso | 2011 |
Isoniazid-resistant intracranial tuberculoma treated with a combination of moxifloxacin and first-line anti-tuberculosis medication.
Topics: Antitubercular Agents; Aza Compounds; Biopsy; Brain; Cerebrospinal Fluid; Drug Resistance, Bacterial | 2011 |
Acute liver failure in a pediatric patient with disseminated tuberculosis.
Topics: Antifungal Agents; Antitubercular Agents; Child; Coccidioidomycosis; Drug Therapy, Combination; Etha | 2011 |
Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.
Topics: Antitubercular Agents; Computer Simulation; Drug Resistance, Multiple, Bacterial; Humans; Isoniazid; | 2011 |
Therapeutic drug monitoring in the treatment of tuberculosis patients.
Topics: Adult; Aged; Alcoholism; Antibiotics, Antitubercular; Antitubercular Agents; Chromatography, High Pr | 2012 |
Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Genotype; Humans; Hydrogen-Ion C | 2012 |
Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea.
Topics: Adult; Amidohydrolases; Antitubercular Agents; Bacterial Proteins; Base Sequence; DNA Mutational Ana | 2012 |
Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Cambodia; DNA, Bacterial; Fluoroquinolones; Genotype; Humans | 2012 |
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BAL | 2012 |
Multidrug-resistant tuberculosis that required 2 years for diagnosis.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Diagnosis, Differential; Humans; Male; Ofloxacin; | 2012 |
Extra-pulmonary primary multidrug-resistant tubercular lymphadenitis in an HIV negative patient.
Topics: Adult; Antitubercular Agents; Clarithromycin; Clofazimine; Cycloserine; Diagnosis, Differential; Dru | 2012 |
Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; | 2012 |
[Characteristics of pncA gene in multidrug-resistant Mycobacterium tuberculosis isolates and its correlation with drug resistance to pyrazinamide].
Topics: Antitubercular Agents; DNA, Bacterial; Humans; Mutation; Mycobacterium tuberculosis; Pyrazinamide; T | 2012 |
Evaluation of tuberculosis underreporting in Greece through comparison with anti-tuberculosis drug consumption.
Topics: Antitubercular Agents; Epidemiological Monitoring; Ethambutol; Greece; Humans; Isoniazid; Latent Tub | 2012 |
Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico.
Topics: Adult; Amidohydrolases; Antitubercular Agents; Female; Humans; Male; Mexico; Middle Aged; Mutation; | 2013 |
Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Anti-Infective Agents; Antitubercular Agents; Female; Humans; Levofloxacin; Male; | 2002 |
Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Drug Combin | 2002 |
Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotics, Antitubercular; Child; Drug Therapy, Co | 2002 |
Drug-resistant Mycobacterium tuberculosis among new tuberculosis patients, Yangon, Myanmar.
Topics: AIDS-Related Opportunistic Infections; Drug Resistance, Bacterial; Ethambutol; Humans; Isoniazid; My | 2003 |
The decline of high drug resistance rate of pulmonary Mycobacterium tuberculosis isolates from a southern Taiwan medical centre, 1996-2000.
Topics: Antitubercular Agents; Cycloserine; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial | 2003 |
Treatment outcome of tuberculosis among Saudi nationals: role of drug resistance and compliance.
Topics: Antibiotics, Antitubercular; Female; Humans; Isoniazid; Male; Mycobacterium tuberculosis; Prevalence | 2003 |
[The short-term and long-term treatment outcomes in patients with pulmonary tuberculosis positive for drug-resistant and sensitive strains].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Drug Therapy, Combination; | 2003 |
Pharmacokinetics of ofloxacin in drug-resistant tuberculosis.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Area Under Curve; Chromatography, High Pressure | 2003 |
Successful treatment of advanced isonizid- and streptomycin-resistant pulmonary tuberculosis with ethionamide, pyrazinamide, and isoniazid.
Topics: Drug Resistance; Drug Resistance, Microbial; Ethionamide; Humans; Isoniazid; Pyrazinamide; Streptomy | 1962 |
RE-TREATMENT OF DRUG-RESISTANT PULMONARY TUBERCULOSIS AT BATTEY STATE HOSPITAL.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial; | 1964 |
THE USE OF ETHIONAMIDE IN COMBINED DRUG REGIMENS IN THE RE-TREATMENT OF ISONIAZID-RESISTANT PULMONARY TUBERCULOSIS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resi | 1965 |
[A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis].
Topics: Adolescent; Adult; Antitubercular Agents; Capreomycin; Drug Therapy, Combination; Female; Humans; Le | 2003 |
[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Topics: Adult; Aged; Antitubercular Agents; Cohort Studies; Drug Therapy, Combination; Female; Humans; Isoni | 2003 |
Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons, Peru.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Resistance, Multiple, Bacter | 2003 |
Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Antitubercular Agents; Cohort Studi | 2004 |
Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray.
Topics: DNA, Bacterial; Drug Resistance, Bacterial; Gene Expression Profiling; Humans; Microbial Sensitivity | 2004 |
Rapid, automated, nonradiometric susceptibility testing of Mycobacterium tuberculosis complex to four first-line antituberculous drugs used in standard short-course chemotherapy.
Topics: Antitubercular Agents; Colony Count, Microbial; Culture Media; Drug Resistance, Multiple, Bacterial; | 2004 |
Treatment outcome of multidrug-resistant tuberculosis among Vietnamese immigrants.
Topics: Capreomycin; Cycloserine; Drug Therapy, Combination; Emigration and Immigration; Ethambutol; Ethiona | 2005 |
Multidrug-resistant tuberculous spondylodiscitis: need for aggressive management and drug susceptibility testing of Mycobacterium tuberculosis isolates.
Topics: Anti-Bacterial Agents; Biopsy, Fine-Needle; Bone Transplantation; Cycloserine; Discitis; Drug Therap | 2006 |
High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis.
Topics: Adult; Antitubercular Agents; Carrier State; Chemical and Drug Induced Liver Injury; Dose-Response R | 2005 |
Multidrug-resistant tuberculosis in military recruits.
Topics: Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Female; Humans; Isoniazid; Milit | 2006 |
[Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy].
Topics: Adult; Aminosalicylic Acid; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Cy | 2006 |
Impact of country of origin on drug-resistant tuberculosis among foreign-born persons in British Columbia.
Topics: Adolescent; Adult; Age Factors; Aged; Analysis of Variance; Anti-Bacterial Agents; Antibiotics, Anti | 2006 |
Multidrug-resistant tuberculosis of the ankle: case report.
Topics: Antitubercular Agents; Child, Preschool; Drug Therapy, Combination; Ethambutol; Female; Follow-Up St | 2006 |
Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sens | 2007 |
Trend of anti-tuberculosis drug resistance in Korea, 1994-2004.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Ethambutol; Humans; Isoniazid; Korea; Middle | 2007 |
Nitrate reductase assay for the rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide.
Topics: Antitubercular Agents; Base Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Genes, B | 2008 |
Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases.
Topics: Adolescent; Antibiotic Prophylaxis; Antitubercular Agents; Contact Tracing; Female; Humans; Infant; | 2007 |
Treatment of isoniazid-resistant pulmonary tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug T | 2008 |
Peak plasma rifampicin level in tuberculosis patients with slow culture conversion.
Topics: Adult; Antitubercular Agents; Case-Control Studies; Female; Humans; Male; Mycobacterium; Mycobacteri | 2008 |
Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic.
Topics: Adolescent; Adult; Aminoglycosides; Aminosalicylic Acid; Antitubercular Agents; Child; Cycloserine; | 2008 |
[Exposure to multiresisant tuberculosis: study and follow-up of nine children].
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Environmental Exposure; Female; Follow-U | 2008 |
Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis.
Topics: Acetaminophen; Adult; Capreomycin; Ciprofloxacin; Drug Combinations; Drug Overdose; Ethambutol; Fema | 1994 |
Drugs for tuberculosis.
Topics: Adult; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol; Hum | 1995 |
Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis.
Topics: Adult; Ciprofloxacin; Decision Support Techniques; Decision Trees; Health Personnel; HIV Seronegativ | 1995 |
Drug resistance of Mycobacterium tuberculosis strains isolated from HIV-infected Italian patients: preliminary report from a multicentric study. The Italian Tuberculosis Drug Resistance Study Group.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; HIV Infections; Humans; Isoniazid; It | 1995 |
Preventive therapy for contacts of multidrug-resistant tuberculosis. A Delphi survey.
Topics: Adult; Antitubercular Agents; Ciprofloxacin; Delphi Technique; Humans; Middle Aged; Pyrazinamide; Tu | 1994 |
[Therapy of tuberculosis in the adult].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Dose-Response Relationship, Dru | 1995 |
Transient exacerbation of tuberculous lymphadenitis during chemotherapy in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Ethambutol; Humans; Isoniazid; | 1994 |
Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Pro | 1994 |
[Disseminated tuberculosis with a multiresistant strain of Mycobacterium tuberculosis in an HIV-infected Swiss male].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance, Microbial; Dru | 1993 |
Drug-resistant tuberculosis.
Topics: Drug Resistance, Microbial; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resis | 1993 |
Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; AIDS-Related Opportunistic Infections; Antibiotics, | 1996 |
Bacille Calmette Guérin immunization of health care workers exposed to multidrug-resistant tuberculosis: a decision analysis.
Topics: Antitubercular Agents; BCG Vaccine; Ciprofloxacin; Decision Support Techniques; Health Personnel; Hu | 1996 |
The management of mycobacterial infections in HIV seropositive individuals. Jefferiss Wing Therapeutics and Protocols Group.
Topics: Adrenal Cortex Hormones; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitu | 1996 |
The 5-year outcome of multidrug resistant tuberculosis patients in the Cape Province of South Africa.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Male; Middle Aged; Mycoba | 1996 |
Initial screening for antituberculous drug resistance at an inpatient facility in Leon, Nicaragua.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Drug Resistance, Multiple; Female; Humans; Is | 1997 |
[Pulmonary tuberculosis caused by Mycobacterium bovis with primary resistance to Isoniazide and pyrazinamide].
Topics: Adult; Antitubercular Agents; Humans; Isoniazid; Male; Mycobacterium bovis; Pyrazinamide; Tuberculos | 1997 |
[Surgical treatment of patients with multi-resistant pulmonary tuberculosis--case reports].
Topics: Adult; Antitubercular Agents; Bronchial Fistula; Drug Therapy, Combination; Ethambutol; Fatal Outcom | 1997 |
[Reasons for chronic expectoration--case reports].
Topics: Adult; Aged; Antitubercular Agents; Capreomycin; Cycloserine; Drug Resistance, Microbial; Drug Thera | 1997 |
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Drug Admi | 1998 |
Standardisation of sensitivity tests.
Topics: Antitubercular Agents; Calibration; Drug Resistance, Microbial; Humans; Laboratories; Microbial Sens | 1998 |
Epidemiology of drug-resistant tuberculosis in New Jersey from 1991 to 1995.
Topics: Adult; Age Distribution; Aged; Antitubercular Agents; Confidence Intervals; Ethambutol; Female; Huma | 1998 |
Drug resistant tuberculosis in prisons in Azerbaijan: case study.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Azerbaijan; Humans; Isoniazid; Mycobacterium tub | 1998 |
Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.
Topics: Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Drug Monitoring; Drug Therapy, Comb | 1998 |
Central nervous system tuberculosis after resolution of miliary tuberculosis.
Topics: Antitubercular Agents; Central Nervous System Infections; Dexamethasone; Drug Therapy, Combination; | 1998 |
Drug-resistant tuberculosis of the brain in a two-year-old child.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Brain Diseases; Child, Preschool; Drug Therapy, | 1998 |
[Resistance and multiresistance to antitubercular drugs in Argentina and in other Latin American countries].
Topics: Acquired Immunodeficiency Syndrome; Antitubercular Agents; Argentina; Drug Resistance, Microbial; Dr | 1998 |
Drug-resistant tuberculosis in the Philippines.
Topics: Antitubercular Agents; Drug Resistance, Multiple; Ethambutol; Female; Humans; Incidence; Isoniazid; | 1999 |
Is the treatment of WHO category I tuberculosis with 2HRZE/6HE a defensible practice?
Topics: Antitubercular Agents; Developing Countries; Drug Resistance, Microbial; Drug Therapy, Combination; | 1999 |
[Breast abscess and pregnancy toxemia revealing multidrug resistant tuberculosis].
Topics: Abscess; Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Breas | 1999 |
pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.
Topics: Amidohydrolases; Antitubercular Agents; DNA Fingerprinting; DNA Transposable Elements; DNA, Bacteria | 2000 |
Tuberculosis treatment: dangerous regimens?
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Humans; | 2001 |
Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Female; Humans; Isoniazid; Male; Micr | 2001 |
Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa.
Topics: Africa, Southern; Amidohydrolases; Antitubercular Agents; Genes, Bacterial; Humans; Microbial Sensit | 2001 |